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providers with access to up-to-date, evidence-based recommendations. In general, the recommendations are the 
same as those in the World Health Organization's 2012 Safe Abortion: Technical and Policy Guidance for Health 
Systems, Second Edition. In rare cases, the recommendations have been modified due to the settings where Ipas 
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Uterine evacuation: Replace sharp curettage with aspiration 
or medications 
 
Recommendation:  
Vacuum aspiration or medical abortion should replace sharp curettage (also known as dilatation and 
curettage or D&C) for the treatment of induced, incomplete, or missed abortion performed in the first or 
second trimester of pregnancy.  
 
Strength of recommendation: High 
 
Quality of evidence: Moderate 
 
Last reviewed: June 30, 2015 
 
The World Health Organization (WHO) and the International Federation of Gynecology and Obstetrics (FIGO)  
state that vacuum aspiration or misoprostol-based medication abortion regimens should replace sharp curettage 
(FIGO, 2011; WHO, 2012). In places where no uterine evacuation services exist, vacuum aspiration and medical 
abortion should be introduced.  
 
A recent Cochrane review comparing vacuum aspiration and sharp curettage shows that vacuum aspiration is as 
effective as sharp curettage in ending a pregnancy and reduces procedure time and procedure-related blood loss 
and pain (Tuncalp, Gulmezoglu, & Souza, 2010). In a retrospective case series of 80,437 women, vacuum 
aspiration was associated with less than half the rate of major and minor complications compared to sharp 
curettage (Grimes, Schulz, Cates Jr., & Tyler, 1976). Multiple studies on induced and postabortion care have 
shown that because vacuum aspiration can be performed in an outpatient setting by physicians or midlevel 
providers without general anaesthesia, the costs to both the health system and women are significantly less 
(Benson, Okoh, KrennHrubec, Lazzarino, & Johnston, 2012; Choobun, Khanuengkitkong, & Pinjaroen, 2012; 
Farooq, Javed, Mumtaz, & Naveed, 2011; Johnston, Akhter, & Oliveras, 2012). In addition, women needing 
postabortion care for moderate or severe complications can be treated with vacuum aspiration in place of D&C 
(Benson et al., 2012; Johnston et al., 2012). 
 
Although no trials exist comparing D&C to medical management of induced, incomplete, or missed abortion, the 
safety and tolerability of medical regimens for uterine evacuation are well documented  and appear as effective 
as vacuum aspiration in the management of incomplete abortion (Kulier et al., 2011; Neilson, Gyte, Hickey, 
Vazquez, & Dou, 2013). 
 
The use of sharp curettage to manage incomplete or missed abortion may be associated with Asherman’s 
syndrome (intrauterine adhesions), a condition that causes infertility. A recent retrospective review of one 
tertiary care center’s patient outcomes reported on 884 women who underwent sharp curettage, vacuum 
aspiration or misoprostol for early pregnancy failure (Gilman Barber, Rhone, & Fluker, 2014). In follow-up, six 
women who had been managed with sharp curettage were found to have Asherman’s syndrome, while no cases 
were found in women managed by vacuum aspiration or misoprostol.  
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Young women  
This recommendation is the same for young women. 
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First-trimester vacuum aspiration and medical abortion: 
Screening for ectopic pregnancy 
 
Recommendation:  
Ectopic pregnancy should be considered in women presenting for abortion who also have a 
concerning history or exam.  
 
Strength of recommendation: Strong 
  
Quality of evidence: Moderate 
  
Last reviewed: October 28, 2015 
 
Background 
Although the rate of ectopic pregnancy in women seeking abortion is less than 1% (Edwards & Creinin, 1997), 
ectopic pregnancy is a leading cause of maternal mortality in the first trimester (CDC, 1995; Khan, Wojdyla, Say, 
Gulmezoglu, & Van Look, 2006; WHO, 1985).  
 
Risk factors 
A woman’s medical history and physical exam may indicate an increased risk of ectopic pregnancy; however, 
half of all ectopic pregnancies occur in women with no risk factors and a benign clinical presentation (Stovall, 
Kellerman, Ling, & Buster, 1990). Risk factors with the highest associated risk of ectopic pregnancy in pregnant 
women are shown in this table: 
 
Risk factor Risk of ectopic in the current pregnancy 
Previous ectopic pregnancy 10-15%(Yao & Tulandi, 1997) 
History of tubal surgery, including sterilization 25-50% (Barnhart, 2009) 
IUD in place 25-50% (Barnhart, 2009) 
 
Other risk factors—such as a history of infertility and assisted reproductive technology, a history of genital or 
pelvic infections, multiple partners, early age at first intercourse, and smoking—confer lower risks (Barnhart, 
2009). 
  
Screening 
Providers should screen women for risk factors for ectopic pregnancy during the history and physical exam. A 
screening checklist should include relevant history, such as a history of ectopic pregnancy, tubal ligation, tubal 
surgery or an intrauterine device (IUD) in place. The screening checklist should also include signs and 
symptoms, such as an adnexal mass or pain on examination, or pain and vaginal bleeding. 
  
Treatment for high-risk women 
A woman desiring abortion who has risk factors for ectopic pregnancy with a benign physical exam can be 
evaluated further with ultrasound or serial hCG testing, but access to testing may be limited in low-resource 
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settings (Obed, 2006). A provider may also offer a woman vacuum aspiration with tissue examination to 
confirm the diagnosis of intrauterine pregnancy rather than a medical abortion. A woman with suspicious signs 
and symptoms or a concerning physical exam should be diagnosed and treated as soon as possible or 
transferred immediately to a facility that can manage ectopic pregnancy. Early diagnosis and treatment of 
ectopic pregnancy can help preserve fertility and save women’s lives. 
 
Post-procedure screening 
For women undergoing vacuum aspiration, the products of conception should be strained and examined to 
confirm products of conception in the aspirate. If products of conception are not seen, ectopic pregnancy 
should be suspected and followed closely.   
 
Young women 
This recommendation is the same for young women. 
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First-trimester vacuum aspiration: Success and complication rates 
Key information:  
Vacuum aspiration is effective and safe, with success rates over 98% and complication rates under 2%. 
Serious adverse events during first-trimester vacuum aspiration are very rare.  
 
Quality of evidence: High 
 
Last reviewed: October 28, 2015 
 
Success 
Vacuum aspiration success is defined as an abortion requiring no further intervention. In a large United States-
based observational study of 11,487 first-trimester aspiration abortions done by physicians, nurse practitioners, 
certified nurse midwives and physicians assistants, the need for repeat aspiration due to incomplete abortion 
was 0.28% and ongoing pregnancy was 0.16% (Weitz et al., 2013).  
 
Complication rates 
A 2015 systematic review analyzed 57 studies reporting data for 337,460 first-trimester abortions performed in 
North America, Western Europe, Scandinavia and Australia/New Zealand (White, Carroll, & Grossman, 2015).  
Major complications requiring intervention (such as hemorrhage requiring transfusion or perforation 
necessitating repair) occurred in ≤ 0.1% of procedures; hospitalization was necessary in ≤ 0.5% of cases. Studies 
looking at different cadres of providers (physicians, nurses, nurse midwives, etc.) in other settings have had 
similar results (Hakim-Elahi, Tovell, & Burnhill, 1990; Jejeebhoy et al., 2011; Warriner et al., 2006). Complication 
rates are lower with more experienced providers (Child, Thomas, Rees, & MacKenzie, 2001).  
 
A U.S. retrospective cohort study comparing first-trimester aspiration abortion complication rates looked at one 
group of 597 women with at least one medical comorbidity (diabetes, hypertension, obesity, HIV, epilepsy, 
asthma, thyroid disease and bleeding/clotting disorders) and another group of 1,363 women without 
comorbidities and found an overall complication rate of 2.9% with no difference between the two groups 
(Guiahi, Schiller, Sheeder, & Teal, 2015). 
 
Mortality rates 
In the United States, the mortality rate from legal induced abortion is 0.64 deaths per 100,000 reported 
abortions (Pazol, Creanga, Zane, Burley, & Jamieson, 2013). In comparison, in the United States in 2009 the 
mortality rate from live birth was 17.8 deaths per 100,000 live births (Centers for Disease Control and 
Prevention, 2013). In the 2015 systematic review referenced above, no deaths were reported (White, Carroll, & 
Grossman, 2015). 
 
Young women 
Young women and adolescents have similar success and lower complication rates for first-trimester vacuum 
aspiration (Cates, Schulz, & Grimes, 1983).  
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Complication rates by study 
 
 Upadyay, 2015 Weitz, 2013 Jejeebhoy, 2011 Warriner, 2006 Hakim-Elahi, 1990 
Number of 
women 
34,744 11,487 897 2,789 170,000 
Location USA USA India South Africa and 
Vietnam 
USA 
Provider type Not specified Physicians and 
newly trained 
nurse 
practitioners, 
certified nurse 
midwives and 
physician 
assistants 
Newly trained 
physicians and 
nurses 
Experienced 
physicians, 
midwives and 
doctor-assistants 
Experienced 
physicians 
Time period 
 
2009-2010 2007- 2011 2009-2010 2003-2004 1971-1987 
Total minor 
complication rate 
1.1% 1.3% 1% (all reported 
as incomplete 
abortion) 
1% 0.85% 
Incomplete 
abortion 
0.33% 0.3% 1% 0.9% Not reported 
(0.35% re-
aspiration rate) 
Ongoing 
pregnancy 
0.04% 0.16% Not reported Not reported 0% 
Minor infection 
 
0.27% 0.12% Not reported 0.1% 0.5% 
Uncomplicated 
perforation 
0.01% 0.03% 0% 0% 0% 
Total major 
complication rate 
0.16% 0.05%  
(6 complications: 
2 perforations, 3 
infections and 1 
hemorrhage) 
0.12%  
(1 complication: 1 
high fever) 
0% 0.07% 
(hospitalizations 
for perforation, 
ectopic 
pregnancy, 
hemorrhage, 
sepsis or 
incomplete 
abortion) 
 
  
Clinical Updates in Reproductive Health                        www.ipas.org/clinicalupdates 
 
                                                                          12 
 
 
References  
Cates Jr, W., Schulz, K. F., & Grimes, D. A. (1983). The risks associated with teenage abortion. New England Journal of 
Medicine, 309(11), 621-624.  
 
Centers for Disease Control and Prevention. (2015). Pregnancy mortality surveillance system. Retrieved from 
http://www.cdc.gov/reproductivehealth/MaternalInfantHealth/PMSS.html 
 
Guiahi, M., Schiller, G., Sheeder, J., & Teal, S. (2015). Safety of first-trimester uterine evacuation in the 
outpatient setting for women with common chronic conditions. Contraception, 92(5), 453-7. 
 
Hakim-Elahi, E., Tovell, H., & Burnhill, M. (1990). Complications of first-trimester abortion: a report of 170,000 cases. 
Obstetrics & Gynecology, 76(1), 129-135. 
 
Jejeebhoy, S. J., Kalyanwala, S., Zavier, A., Kumar, R., Mundle, S., Tank, J., Jha, N. (2011). Can nurses perform manual 
vacuum aspiration (MVA) as safely and effectively as physicians? Evidence from India. Contraception, 84(6), 615-621. 
 
Pazol, K., Creanga, A. A., Burley, K. B., Hayes, B., & Jamieson, D. J. (2013). Abortion Surveillance - United States, 
2010. Morbidity and Mortality Weekly Report, 62(8), 1-48. 
 
Upadhyay, U. D., Desai, S., Zlidar, V., Weitz, T. A., Grossman, D., Anderson, P., & Taylor, D. (2015). Incidence of 
emergency department visits and complications after abortion. Obstetrics & Gynecology, 125(1), 175-83. 
 
Warriner, I. K., Meirik, O., Hoffman, M., Morroni, C., Harries, J., My Huong, N., Seuc, A. H. (2006). Rates of 
complication in first-trimester manual vacuum aspiration abortion done by doctors and midlevel providers in South 
Africa and Vietnam: a randomised controlled equivalence trial. The Lancet, 368(9551), 1965-1972.  
 
Weitz, T. A., Taylor, D., Desai, S., Upadhyay, U. D., Waldman, J., Battistelli, M. F., & Drey, E. A. (2013). Safety of 
aspiration abortion performed by nurse practitioners, certified nurse midwives, and physician assistants under a 
California legal waiver. American Journal of Public Health, 103(3), 454-461. 
 
White, K., Carroll, E., & Grossman, D. (2015). Complications from first-trimester aspiration abortion: a systematic 
review of the literature. Contraception, 92, 422-438. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Updates in Reproductive Health                        www.ipas.org/clinicalupdates 
 
                                                                          13 
 
First-trimester vacuum aspiration: Safety for adolescent 
and young women 
 
Recommendation:  
 Vacuum aspiration for adolescent and young women is very safe and should be offered as a 
method of safe abortion.  
 Cervical preparation may be considered for young adolescents prior to vacuum aspiration 
due to their increased risk of cervical injury. 
 Clinical services should promote timely access to safe abortion for young women.  
 
Strength of recommendation: Strong 
  
Quality of evidence: Moderate 
  
Last reviewed: October 20, 2015 
 
Background 
The World Health Organization (WHO) defines adolescents as individuals 10-19 years of age, and young 
women as 20-24 years of age. Adolescents face barriers to accessing safe abortion care and present for 
abortions at later gestational ages than adult women (Pazol, Creanga, Zane, Burley, & Jamieson, 2012; 
Sowmini, 2013). Adolescents are at increased risk of complications of unsafe abortion due to delays seeking 
care, seeking care from unskilled providers and not accessing services when complications arise (Olukoya, 
Kaya, Ferguson, & AbouZahr, 2001). Increasing access to safe abortion is beneficial for young women. 
 
Safety of vacuum aspiration 
A large prospective United States multicenter cohort study of 164,000 women undergoing legal abortion, 
50,000 of whom were adolescents, found that mortality and major morbidity were lower in adolescents 
(Cates Jr., Schulz, & Grimes, 1983). The mortality rate was 1.3 per 100,000 in women under 20 years old 
compared to 2.2 per 100,000 in women age 20 and older. Serious adverse events including major surgery, 
hemorrhage with transfusion, and uterine perforation were less common in women under age 20.   
 
Cervical injury 
In large prospective cohort studies, very young age (<17 years old) has been associated with cervical injury 
during vacuum aspiration even after controlling for nulliparity (Cates Jr. et al., 1983; Schulz, Grimes, & Cates, 
1983). Cervical preparation may be considered for young women prior to first-trimester vacuum aspiration 
(Allen & Goldberg, 2007; WHO, 2012).  
 
Subsequent perinatal outcomes 
Three studies have examined perinatal outcomes in pregnancies in adolescent and young women who have 
had a previous abortion (van Veen, Haeri, & Baker, 2015; Lao & Ho, 1998; Reime, Schucking, & Wenzlaff, 
2008). None of the studies—a US-based retrospective cohort study comparing 654 nulliparous adolescent 
deliveries to 102 adolescent deliveries with a prior abortion (van Veen, Haeri, & Baker, 2015), a German 
retrospective cohort including 7,845 nulliparous adolescent deliveries and 211 adolescent deliveries with one 
prior induced abortion (Reime, Schucking, & Wenzlaff, 2008) and a Hong Kong case-control study comparing 
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118 adolescent deliveries with one or more prior abortions to 118 age- and parity-matched controls (Lao & 
Ho, 1998) —found any differences in adverse perinatal outcomes between study groups. Method of abortion 
was not specified in any of these studies. 
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First-trimester vacuum aspiration: Midlevel providers 
 
Recommendation:  
Most cadres of trained midlevel providers can provide first-trimester vacuum aspiration abortion as 
safely and effectively as physicians (WHO, 2015). 
 
Strength of recommendation: Strong 
  
Quality of evidence: High 
  
Last reviewed: October 26, 2015 
 
Background 
Access to safe abortion or postabortion care can be increased by expanding the provider base to include 
midlevel providers. Midlevel providers include cadres of health-care providers other than physicians such as 
nurses, nurse midwives, clinical officers and others. 
 
Evidence 
A 2015 systematic review compiled data from five studies comparing provision of surgical abortion by midlevel 
providers to that of doctors (Barnard, Kim, Park, & Ngo, 2015). Included studies were from the United States, 
India, Vietnam and South Africa. There was no difference in total complication rates, and a very slightly 
increased risk of incomplete abortion when done by midlevel providers. The similarity in safety and efficacy is 
true for both experienced and newly trained providers (Jejeebhoy et al., 2011; Warriner et al., 2006).  
 
The World Health Organization (WHO) recommends that non-specialist doctors, associate and advanced 
associate clinicians, midwives and nurses can perform vacuum aspiration for induced abortion. In settings 
where there are established mechanisms to include auxiliary nurses and auxiliary nurse midwives in basic 
emergency obstetric care or postabortion care, these cadres can also perform vacuum aspiration. Where 
doctors of complementary medicine participate in other tasks related to maternal and reproductive health, 
they can also perform vacuum aspiration (WHO, 2015). 
 
Young women 
This recommendation is the same for young women. 
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First-trimester vacuum aspiration: Cervical preparation 
 
Recommendation:  
Cervical preparation is recommended after 12-14 weeks. Before 12-14 weeks, cervical preparation 
may be offered but does not need to be routinely used (WHO, 2012). 
 
Recommended methods for cervical preparation in the first trimester include:  
 Misoprostol 400mcg sublingually 2-3 hours before the procedure 
 Misoprostol 400mcg vaginally three hours before the procedure 
 Mifepristone 200mg orally 24-48 hours before the procedure 
 Osmotic dilators placed in the cervix 6-24 hours before the procedure 
 
Strength of recommendation: Strong 
  
Quality of evidence: Moderate 
  
Last reviewed: October 20, 2015 
 
Background 
Cervical preparation is recommended before surgical abortion for all women over 12-14 weeks gestation to 
prevent complications (Fox & Hayes, 2007; Kapp, Lohr, Ngo, & Hayes, 2010; WHO, 2012). For women at higher 
risk of complications (young women, nulliparous women, women with cervical abnormalities, or women at later 
gestational ages) or inexperienced providers there may be a benefit from cervical preparation even before 12-
14 weeks gestation (Allen & Goldberg, 2007; Grimes, Schulz, & Cates, 1984; Kaunitz, Rovira, Grimes, & Schulz, 
1985).  
 
Benefits of cervical preparation 
A meta-analysis of 51 randomized controlled clinical trials of cervical preparation in the first trimester showed 
that procedure time was shorter with cervical preparation but there was no difference in serious outcomes like 
cervical laceration or uterine perforation in women who were given cervical preparation compared to placebo 
(Kapp et al., 2010). The largest multicenter randomized controlled trial of 4,972 women given misoprostol 
400mcg vaginally or placebo three hours before a vacuum aspiration showed no difference in the rates of 
cervical laceration, perforation or infection between the two groups. In this study, the risk of incomplete 
abortion was lower in the misoprostol group (<1%) compared to the placebo group (2%), but side-effects were 
more frequent for women who took misoprostol (Meirik, Huong, Piaggio, Bergel, & von Hertzen, 2012).   
 
Side-effects of cervical preparation 
In randomized controlled trials, side-effects of cervical preparation are common (Kapp & vonHertzen, 2009; 
Meirik et al., 2012). In the largest randomized controlled trial of misoprostol, 55%of women who took 
misoprostol complained of abdominal pain and 37% had vaginal bleeding, compared to 22%and 7% in the 
placebo group (Meirik et al., 2012). In addition, cervical preparation adds cost, complexity and time to an 
abortion, as women must visit the clinic a day before the procedure to get osmotic dilators or mifepristone or 
wait in the clinic for 2-3 hours for misoprostol to work. Because first-trimester abortion is so safe, the 
gestational age at which the benefit of cervical preparation outweighs the side-effects is not known (Kapp et al., 
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2010). Women’s satisfaction with cervical preparation has not been studied in randomized controlled trials 
(Kapp et al., 2010) but is an important consideration for quality of care and service delivery. 
 
Choice of methods 
If cervical preparation is used, the choice of vaginal or sublingual misoprostol, oral mifepristone or osmotic 
dilators may be based on availability, expense, convenience and preference. Sublingual misoprostol has 
superior efficacy but more gastrointestinal side effects than vaginal misoprostol (Kapp et al., 2010). 
Mifepristone given 24 hours prior to the abortion is superior to misoprostol but adds time and expense to the 
abortion procedure (Ashok, Flett, & Templeton, 2000). Misoprostol and laminaria have similar efficacy but 
laminaria placement has increased pain, increased time to procedure and reduced satisfaction for women 
(Burnett, Corbett, & Gertenstein, 2005; MacIsaac, Grossman, Balistreri, & Darney, 1999). 
 
Young women 
Young women may benefit from cervical preparation due to their increased risk of cervical injury during 
abortion (Schulz, Grimes, & Cates, 1983), but there are no clinical trial data to support the use of cervical 
preparation in this patient population.  
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First-trimester vacuum aspiration: Paracervical anesthesia 
 
Recommendation:  
 Paracervical anesthesia is recommended as a component of pain management during first-
trimester vacuum aspiration procedures. 
 Midlevel providers may give paracervical anesthesia during first-trimester aspiration 
procedures. 
 
Strength of recommendation: Strong  
  
Quality of evidence: Moderate 
  
Last reviewed: October 21, 2015 
 
Evidence 
Many providers use local anesthesia or paracervical block (PCB) for pain management during first-trimester 
vacuum aspiration (O’Connell et al., 2009). A 2013 systematic review evaluating PCB for gynecologic procedures 
requiring cervical dilation, including abortion, found that PCB reduced pain during cervical dilation and uterine 
interventions, although not postprocedure pain, when compared to placebo or no anesthesia 
(Tangsiriwatthana, Sangkomkamhang, Lumbiganon, & Laopaiboon, 2013). In a recent, high-quality randomized 
controlled trial of 120 women undergoing first-trimester aspiration abortion, women who received PCB had less 
pain during dilation and aspiration compared to women who received a sham injection. In this study, the 
overall rate of complications was low and there was no difference between the two groups (Renner, 2012).  
 
Technique (Renner, 2012)   
 Load a 20mL syringe with 18mL of lidocaine (1%) buffered with 2mL sodium bicarbonate (8.4%). 
 Attach syringe to a 20-gauge spinal needle.  
 Infiltrate 2mL into the cervix superficially at the tenaculum site (located at 12 o'clock). 
 Grasp the cervix with the single-tooth tenaculum. 
 Inject the remaining 18mL in equal amounts at the cervicovaginal junction at the locations of two, four, 
eight and 10 o'clock. The injection should be continuous from superficial to a depth of three 
centimeters.  
 Pull back on the plunger before injecting anesthesia to prevent intravascular injection.  
 Begin dilation three minutes after the PCB is complete. 
 
Midlevel providers 
In an international randomized multicenter study comparing 2,894 first-trimester procedures done by 
physicians and midlevel providers, midlevel providers had similar safety and efficacy rates as physicians when 
performing vacuum aspiration with paracervical block (Warriner et al., 2006). The midlevel providers did not 
have any complications related to use of paracervical anesthesia.   
 
Young women  
This recommendation is the same for young women.    
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First-trimester vacuum aspiration: Pain management 
 
Recommendation:  
 Women undergoing first-trimester vacuum aspiration should receive pain medications and 
non-pharmacologic approaches to treat pain (WHO, 2012).  
 General anesthesia is not routinely recommended for first-trimester pain management. 
 
Strength of recommendation: Strong 
 
Quality of evidence: Moderate 
 
Last reviewed: October 24, 2015 
 
Background 
Most women undergoing first-trimester vacuum aspiration will experience pain (Smith, Stubblefield, 
Chirchirillo, & McCarthy, 1979). Clinicians consistently underestimate the amount of pain women experience 
during abortion (Singh et al., 2008).  
  
Methods of pain management 
For first-trimester vacuum aspiration, a combination of pain medications, local anesthesia (in the form of a 
paracervical block), and non-pharmacologic measures typically provide pain relief for most women (WHO, 
2012; Renner et al., 2010). Intravenous sedation may also be offered. General anesthesia increases the risks 
associated with abortion and is not recommended for routine procedures (Atrash, Cheek, & Hogue, 1988).   
  
Pain medication 
Premedication with non-steroidal anti-inflammatory drugs has been shown in clinical trials to decrease pain 
during and after the procedure (Roche, Li, James, Fechner & Tilak, 2012; Romero, Turok, & Gilliam, 2008; 
Suprapto & Reed, 1984; Wiebe & Rawling, 1995); both oral and intramuscular non-steroidal anti-inflammatory 
medications are effective (Braaten, Hurwitz, Fortin & Goldberg, 2013). Premedication with narcotic analgesics 
also provides pain relief but may be less effective than non-steroidal anti-inflammatory drugs (Khazin et al., 
2011; Lowenstein et al., 2006; Romero, Turok & Gilliam, 2008). A randomized controlled trial of hydrocodone-
acetaminophen compared to placebo showed that the addition of hydrocodone-acetaminophen to standard 
premedication with ibuprofen did not improve pain management and increased postoperative nausea (Micks et 
al., 2012).  Anxiolytics such as lorazepam or midazolam may decrease anxiety related to the procedure and 
cause amnesia for some women, but do not affect pain (Bayer et al., 2015; Wiebe, Podhradsky, & Dijak, 2003). 
Paracetamol is not effective for pain relief during vacuum aspiration (Cade & Ashley, 1993).   
  
Local anesthesia 
A paracervical block with 20mL of lidocaine (1%) given three minutes before dilating the cervix has been shown 
to decrease pain with dilation and aspiration (Renner, Nichols, Jensen, Li, & Edelman, 2012). Paracervical block 
is a low risk procedure that can be performed by physicians and midlevel providers (Warriner et al., 2006).   
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Non-pharmacologic pain management 
Medications should be supplemented with supportive techniques to decrease pain and anxiety. Some 
techniques that may be helpful include respectful staff; a clean, secure and private setting; counseling; verbal 
support; gentle surgical technique; and a heating pad or hot water bottle in the recovery room. One small trial 
randomizing 214 women to doula support or usual care during their abortion procedures found no differences 
in pain or satisfaction with procedure, although women who received doula support overwhelmingly 
recommended it (Chor et al., 2015). In small studies, listening to music has not been shown to improve pain 
relief, and may increase pain perception for some women (Guerrero et al., 2012; Wu et al., 2012).  
 
Intravenous sedation 
Intravenous sedation using a combination of narcotics and anxiolytics is an effective means of pain control and 
improves satisfaction with the abortion procedure (Allen, Kumar, Fitzmaurice, Lifford, & Goldberg, 2006; Wong, 
Ng, Ngai, & Ho, 2002). However, providing intravenous sedation increases the expense, complexity and 
potential risks of an abortion procedure. The increased monitoring necessary to deliver intravenous sedation 
safely requires facility investments in training and equipment.   
  
Young women 
Young and nulliparous women report increased pain during abortion procedures (Belanger, Melzack, & Lauzon, 
1989; Smith et al., 1979). Being attentive to young women’s needs for pain management increases the quality 
of abortion care.   
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First-trimester vacuum aspiration: Prophylactic antibiotics 
 
Recommendation:  
Administer prophylactic antibiotics for all women prior to vacuum aspiration (WHO, 2012). Where 
antibiotics are unavailable, uterine aspiration may still be offered. Therapeutic antibiotics should be 
administered to all women who are suspected of or who have been diagnosed with an infection. 
 
Strength of recommendation: Strong 
 
Quality of evidence: High 
 
Last reviewed: October 23, 2015 
 
Background 
A Cochrane meta-analysis of 19 randomized controlled clinical trials showed that administration of prophylactic 
antibiotics at the time of vacuum aspiration in the first trimester significantly reduces the risk of postabortal 
infection (Low, Mueller, Van Vliet, & Kapp, 2012). The World Health Organization (2012), Society of Family 
Planning (Achilles & Reeves, 2011), American Congress of Obstetricians and Gynecologists (2009) and Royal 
College of Obstetricians and Gynaecologists (2011) recommend prophylactic antibiotics for all women having a 
vacuum aspiration. Giving prophylactic antibiotics is more effective (Levallois & Rioux, 1988) and cheaper 
(Penney et al., 1998) than screening all women and treating only those with evidence of infection. The inability 
to provide antibiotics should not limit access to abortion (WHO, 2012), as the overall risk of infection with 
vacuum aspiration is very low. 
 
Regimen 
Many antibiotic regimens for abortion prophylaxis have been studied, but the ideal antibiotic, dose and timing 
has not yet been established (Achilles & Reeves, 2011; Low, Mueller, Van Vliet, & Kapp, 2012). Tetracyclines 
(doxycycline) and nitroimidazoles (metronidazole and tinidizole) are commonly used because of their clinical 
efficacy, oral availability, low cost and low risk of allergic reactions (Achilles & Reeves, 2011). Although studies 
of abortion are limited, (Caruso et al., 2008) evidence from the obstetrical (Costantine et al., 2008), gynecologic 
(Mittendorf et al., 1993) and general surgery (Classen et al., 1992) literature supports the practice of giving 
antibiotics before the procedure to decrease the risk of infection. Antibiotic regimens do not need to be 
extended beyond the immediate postabortion period (Achilles & Reeves, 2011; Levallois & Rioux, 1988; Caruso, 
et al., 2008; Lichtenberg & Shott, 2003). 
 
The following table lists regimens recommended by professional organizations. These regimens are based on 
clinical evidence and expert opinion. Providers should choose a regimen based on the expense and availability 
of the antibiotics as well as practices around testing and treating women for sexually transmitted infections.  
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Common Regimens Recommender 
Doxycycline 100mg orally 1 hour before the 
procedure and 200mg after the procedure 
or 
Metronidazole 500mg orally twice daily for 5 days 
American College of Obstetricians and Gynecologists 
(2009) 
Doxycycline 200mg orally before the procedure 
or 
Azithromycin 500mg orally before the procedure 
or  
Metronidazole 500mg orally before the procedure 
Planned Parenthood Federation of America (PPFA 
Manual of Medical Standards and Guidelines, 2014) 
 
Therapeutic antibiotics 
If possible, women at high risk should be screened and treated for sexually transmitted infections in addition to 
receiving prophylactic antibiotics. Women who have signs and symptoms of active infection should be provided 
with abortion services without delay and treated appropriately once the procedure is completed. 
 
Young women 
This recommendation is the same for young women.   
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First-trimester vacuum aspiration: Postabortion 
contraception 
 
Recommendation:  
 Immediate initiation of hormonal and non-hormonal contraception and sterilization following 
first-trimester aspiration abortion is encouraged and considered safe.  
 Intrauterine device (IUD) placement or female sterilization can be performed immediately 
following a successful, uncomplicated abortion.  
 Long-acting contraceptive methods have higher continuation rates and lower repeat 
pregnancy rates compared to short-acting methods.  
 
Strength of recommendation: Strong 
 
Quality of evidence: 
 IUDs and combined oral contraceptives: High 
 Other methods: Low to Moderate 
 
Last reviewed: October 27, 2015 
 
Fertility return 
A woman may ovulate within 10 days of an abortion (Boyd et al., 1972) and can become pregnant if she 
resumes sexual intercourse without using a modern contraceptive method. 
 
Safety and acceptability of postabortion contraception 
The World Health Organization’s (WHO) 2015 Medical Eligibility Criteria for Contraceptive Use classifies all 
contraceptive methods as category one, or safe for immediate use, following first-trimester uncomplicated 
aspiration abortion. Sterilization is classified as acceptable after an uncomplicated abortion. Male sterilization 
may be performed at any time. Fertility awareness-based methods may be initiated once a woman has had at 
least one postabortion menses.  
 
In comparison to short-acting methods such as oral contraceptive pills, long-acting methods of birth control 
such as implants and IUDs have higher continuation rates and lower repeat pregnancy and abortion rates than 
other methods (Rose, Garrett, & Stanley, 2015; Pohjoranta, Mentual, Gissler, Suhonen, & Heikinheimo, 2015; 
Blumenthal, Wilson, Remsburg, Cullins & Huggins, 1994; Cameron et al., 2012; Langston, Joslin-Rohr, & 
Westhoff, 2014; Peipert, Madden, Allsworth, & Secura, 2012; Roberts, Silva, & Xu, 2010).  
 
Evidence related to specific contraceptive methods 
Progestin-only subdermal implants: Cohorts of women using the etonogestrel contraceptive implant 
immediately after abortion show high continuation rates, similar to those of women with interval placement 
(Madden et al., 2012; Mark, Borgatta, & Sonalkar, 2013).  
 
Intrauterine devices (IUDs): A 2010 Cochrane review of eleven randomized trials with 7,405 women concluded 
that IUD insertion immediately after abortion is safe and practical (Grimes, Lopez, Schulz, & Stanwood, 2010). 
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This review found no differences in serious adverse events, such as infection or perforation, between 
immediate and delayed placement. Expulsion rates were slightly higher with immediate insertion but so were 
long-term continuation rates. In a recent randomized controlled trial that assigned 575 women to either 
immediate or delayed insertion, those with delayed insertion were less likely to obtain the device and more 
likely to have a repeat pregnancy (Bednarek et al., 2011). Requiring a follow-up visit for IUD insertion is a 
significant barrier to obtaining the IUD (Stanek, Bednarek, Nichols, Jensen, & Edelman, 2009).  
 
Progestin-only injection: A study of 132 women using depot medroxyprogesterone acetate immediately after 
abortion reported no serious adverse events but low method continuation rates (22%) at one year and high 
repeat pregnancy rates (Goldberg, Cardenas, Hubbard, & Darney, 2002).   
 
Combined oral contraceptives (COCs): A recent review of seven studies including 1,739 women demonstrated 
no serious adverse events using COCs immediately after abortion (Gaffield, Kapp, & Ravi, 2009). Additionally, 
women who used COCs immediately demonstrate similar bleeding patterns to women using no contraception, 
and less bleeding than copper IUD users. 
 
Combined vaginal ring: A cohort study of 81 women who placed a vaginal ring one week after abortion showed 
no serious adverse events or infections (Fine, Tryggestad, Meyers, & Sangi-Haghpeykar, 2007).  
 
Combined contraceptive patch: A trial of 298 women randomized to either immediate postabortion start or 
delayed start the Sunday after an abortion showed no difference in continuation rates at two and six months. In 
the 53% of women who were able to be contacted at six months, half had stopped using the contraceptive 
patch (Steinauer, Sokoloff, Roberts, Drey, Dehlendorf, & Prager, 2014). 
 
Young women 
The IUD for women under the age of 20 is classified by WHO as category two, in which the benefits generally 
outweigh the risks. While risk is slightly increased due to higher rates of sexually transmitted infections and 
expulsion in this patient population, IUDs are still a safe, effective and recommended method for women under 
the age of 20. Depot medroxyprogesterone acetate injection is also classified by WHO as a category two for 
women under 18 years of age, due to theoretical concerns about bone mineral density. Sterilization may be 
performed, but a young woman will need special precautions due to the increased risk of regret (WHO, 2015). 
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First-trimester vacuum aspiration: Postabortion IUD use    
Recommendation: 
 Intrauterine contraceptive device (IUD) placement can be performed immediately following a 
successful, uncomplicated abortion.  
 Long-acting contraceptive methods have higher continuation rates and lower repeat pregnancy 
rates compared to short-acting methods. 
 
Strength of recommendation: Strong 
  
Quality of evidence: High 
  
Last reviewed:  October 27, 2015 
 
Fertility return 
A woman may ovulate within 10 days of an abortion (Boyd et al., 1972) and can become pregnant if she resumes 
sexual intercourse without using a modern contraceptive method. 
 
Safety and acceptability of postabortion contraception 
The World Health Organization’s (WHO) 2015 Medical Eligibility Criteria for Contraceptive Use classifies 
intrauterine contraceptive devices (IUDs) as category one, or safe for immediate use, following first-trimester 
uncomplicated aspiration abortion.  
 
In comparison to short-acting methods of birth control such as oral contraceptive pills, long-acting methods such as 
implants and IUDs have higher continuation rates and lower repeat pregnancy and abortion rates (Pohjoranta, 
Mentula, Gissler, Suhonen, & Heikinheimo, 2015; Blumenthal, Wilson, Remsburg, Cullins, & Huggins, 1994; 
Cameron et al., 2012; Langston, Joslin-Rohr, & Westhoff, 2014; Peipert, Madden, Allsworth, & Secura, 2012; 
Roberts, Silva, & Xu, 2010). Although rates of IUD expulsion are slightly higher following immediate postabortion 
insertion (5% compared to 2.7% after delayed insertion), continuation rates at six months are significantly higher 
than for patients who await interval insertion (Bednarek et al., 2011; Grimes, Lopez, Shulz, & Stanwood, 2010). 
Requiring a follow-up visit for IUD insertion is a significant barrier to obtaining an IUD (Stanek, Bednarek, Nichols, 
Jensen, & Edelman, 2009). A 2015 randomized controlled trial comparing the Cu-IUD to the LNG-IUS inserted 
immediately following first-trimester vacuum aspiration found no differences in expulsion rates (approximately 
12%) or continuation rates at six months (approximately 75%) between the two IUD types (Bilgehan, Dilbaz, 
Karadag, & Deveci, 2015). 
  
Young women 
The IUD for women under the age of 20 is classified by WHO as category two, in which the benefits generally 
outweigh the risks. While risk may be slightly increased due to higher rates of sexually transmitted infections and 
expulsion in this patient population, IUDs are still a safe, effective and recommended method for women under the 
age of 20. 
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First-trimester medical abortion: Safety and efficacy for 
adolescent and young women 
 
Recommendation:  
 Medical abortion for adolescent and young women is safe, effective and acceptable and 
should be offered as a method of safe abortion to this population.  
 Clinical services should promote timely access to safe abortion for young women. 
 
Strength of recommendation: Strong 
 
Quality of evidence: Moderate 
 
Last reviewed: October 20, 2015 
 
Background 
The World Health Organization defines adolescents as individuals 10-19 years of age, and young women as 20-
24 years of age. Adolescents face barriers to accessing safe abortion care and present for abortions at later 
gestational ages than adult women (Pazol, Creanga, Zane, Burley, & Jamieson, 2012; Sowmini, 2013). 
Adolescents are at increased risk of complications of unsafe abortion due to delays seeking care, seeking care 
from unskilled providers and not accessing services when complications arise (Olukoya, Kaya, Ferguson, & 
AbouZahr, 2001). Increasing access to safe abortion, including medical abortion, is beneficial for young women. 
 
Efficacy of medical abortion 
Clinical trials and cohort studies have shown young women have the same (Haimov-Kochman et al., 2007; 
Heikinheimo, Leminen, & Suhonen, 2007) or increased (Niinimäki et al., 2011; Shannon et al., 2006) success 
rates when using mifepristone and misoprostol for medical abortion compared to older women. A large Finnish 
population-based retrospective cohort study that compared 3,024 adolescents to 24,006 adult women up to 20 
weeks gestational age showed that the risk of needing surgical evacuation following medical abortion was 
significantly lower in adolescents (Niinimäki et al., 2011). In a prospective cohort that included young women, 
the efficacy of misoprostol-only medical abortion was the same for young women and older women (Bugalho et 
al., 1996).  
  
Safety of medical abortion 
Despite higher rates of chlamydia infection in adolescents, a large population-based retrospective cohort study 
of women up to 20 weeks gestational age found complication rates were similar or lower among adolescents 
than among adult women, even when controlling for nulliparity. In this study, adolescents had a significantly 
lower incidence of hemorrhage, incomplete abortion, and need for surgical evacuation. Postabortion infection 
occurred at similar rates in adolescents and older women (Niinimäki, et al., 2011). 
  
Acceptability of medical abortion 
In one small, non-comparative study of 28 adolescents age 14-17 using mifepristone and misoprostol medical 
abortion, 96% of adolescents found medical abortion acceptable and 79% reported satisfaction with the 
procedure by four weeks of follow-up (Phelps, Schaff, & Fielding, 2001).   
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First-trimester medical abortion with mifepristone and 
misoprostol or misoprostol only: Midlevel providers 
 
Recommendation:  
Most cadres of trained midlevel providers can provide first-trimester medical abortion as safely and 
effectively as physicians (WHO, 2015). 
 
Strength of recommendation: Strong 
  
Quality of evidence: High 
  
Last reviewed: October 26, 2015 
 
Background 
Access to safe abortion or postabortion care can be increased by expanding the provider base to include non-
physician providers. Midlevel providers include cadres of health-care providers other than physicians such as 
nurses, nurse midwives, clinical officers and others. 
 
Evidence 
A 2015 Cochrane systematic review comparing medical abortion provision by midlevel providers and doctors 
(Barnard, Kim, Park, & Ngo, 2015) included three studies from Nepal, India and Sweden. Midlevel providers in 
the included studies were nurses, auxiliary nurse midwives, ayurvedic (traditional) physicians and midwives. 
The review found no difference in failure or incomplete abortion rates or complication rates when medical 
abortion was provided by midlevel providers or doctors. An additional randomized non-inferiority trial 
published since the review compared provision of medical abortion by nurses and doctors in Mexico and 
found no differences in safety or efficacy (Olavarrieta et al., 2015).     
 
The World Health Organization (WHO) recommends that, in addition to specialist and non-specialist doctors, 
associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives 
can provide medical abortion. Where doctors of complementary medicine participate in other tasks related 
to maternal and reproductive health, they can also provide medical abortion. The WHO makes no 
recommendation regarding provision of medical abortion by pharmacists or lay health workers, based on lack 
of evidence (2015). 
 
Young women 
This recommendation is the same for young women.  
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First-trimester medical abortion with mifepristone and 
misoprostol or misoprostol only: Estimating gestational age 
 
Recommendation:  
Gestational age can be calculated using a woman’s report of her last menstrual period (LMP) 
combined with a clinician’s bimanual exam. Use of routine ultrasound for gestational age 
determination is not necessary (WHO, 2012). 
 
Strength of recommendation: Strong 
 
Quality of evidence: Moderate 
 
Last reviewed: October 24, 2015 
 
Background 
Providers should determine gestational age to assess a woman’s eligibility for medical abortion. Women and 
providers can accurately assess gestational age without routine ultrasound (Kaneshiro, Edelman, Sneeringer, & 
Ponce de Leon, 2011). If gestational age is misestimated, the result is usually not clinically significant because 
any reduction in effectiveness of medical abortion regimens as gestational age advances is gradual, not sudden 
(Hamoda, Ashok, Flett, & Templeton, 2005).    
  
Last menstrual period  
Most women can recall their last menstrual period (LMP) reasonably well regardless of their education and 
whether they usually record their LMP dates (Harper, Ellertson & Winikoff, 2002; Wegienka & Baird, 2005). A 
2014 systematic review assessing accuracy of LMP alone for gestational dating before medical abortion 
included five studies reporting data for more than 7,500 women (Schonberg et al., 2014). Overall, 3-12% of 
women eligible for medical abortion based on LMP were ineligible based on ultrasound. In two multi-site 
international cohort studies of 1,221 women having medical abortion in China, Cuba, India and the United 
States, women were able to estimate their eligibility accurately over 90% percent of the time (Ellertson et al., 
2000; Ellertson, Elul, & Winikoff, 1997).  
  
Bimanual examination 
According to cohort studies of medical abortion, adding a bimanual exam to a woman’s report of her LMP can 
help a clinician accurately determine gestational age (Blanchard et al., 2007; Bracken et al., 2011; Clark et al., 
2010; Clark, Gold, Grossman, & Winikoff, 2007; Fielding, Schaff, & Nam, 2002). A cross-sectional multi-site study 
of 673 women in South Africa found that providers’ estimates of gestational age were, on average, two days 
lower than ultrasound estimate and women’s LMP estimates of gestational age were one day lower. The 
authors concluded that a combination of assessment of menstrual history and physical examination was 
sufficiently accurate to determine eligibility for medical abortion in most cases when compared to ultrasound 
(Blanchard et al., 2007). In a prospective study of 1,016 women at 15 sites in the United States, clinicians 
correctly estimated eligibility in 87% of women. In only 1% of cases did clinicians underestimate gestational age, 
a potentially important error in medical abortion if underestimation is clinically significant (Fielding et al., 2002). 
Finally, a prospective trial of 4,484 women in 10 clinics in the United States showed that if women had 
gestational age estimated by LMP and a clinician exam, only 1.6% of them would have been inappropriately 
Clinical Updates in Reproductive Health                        www.ipas.org/clinicalupdates 
 
                                                                          39 
 
given medical abortion above the gestational age limit compared to when ultrasound was used (Bracken et al., 
2011). 
 
Ultrasound 
Ultrasound does not yield exact gestational age measurements due to variability in the sonographer, machines 
and software (Callen, 2000). In addition, an ultrasound has an inherent margin of error of 3-5 days before 12 
weeks gestation, and the margin of error increases as the pregnancy advances (Hadlock, Shah, Kanon, & 
Lindsey, 1992). For these reasons, if the LMP and ultrasound differ within five days in the first trimester, the 
LMP is usually used for dating. In cohort studies of medical abortion in low-resource settings such as India, 
Nepal, Vietnam and Tunisia, lack of ultrasound has not had an impact on the success of medical abortion (Coyaji 
et al., 2001; Elul et al., 2001; Warriner et al., 2011).   
  
If a provider is unable to assess gestational age through the combination of LMP, history and bimanual 
examination, a more experienced clinician should perform a bimanual examination or the woman should be 
referred for an ultrasound. Any woman with a suspected ectopic pregnancy needs further evaluation.   
  
Young women 
This recommendation is the same for young women. 
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First-trimester medical abortion with mifepristone and 
misoprostol or misoprostol only: Pain management 
 
Recommendation:  
 All women undergoing medical abortion in the first trimester should be offered pain 
management (WHO, 2012). 
 Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or diclofenac are more 
effective than paracetamol or acetaminophen. 
 Narcotic analgesics and non-pharmacologic measures may also be used. 
 
Strength of recommendation: Strong 
 
Quality of evidence: Low 
 
Last reviewed: October 24, 2015 
 
Medications for pain management 
In a study of 6,755 women using medical abortion in the first trimester, 78.4% reported moderate or severe 
pain and cramping when using the regimen (Goldstone, Michelson, & Williamson, 2012). Different pain 
medications for medical abortion have been studied with varying degrees of effectiveness (Jackson & Kapp, 
2011). A randomized controlled trial of 120 women showed that ibuprofen is more effective than 
acetaminophen for pain during first-trimester medical abortion with mifepristone and misoprostol (Livshits et 
al., 2009). Pre-treatment with ibuprofen is no better for pain management than treatment once cramping starts 
(Raymond et al., 2013). Narcotic analgesics are another option for pain control, although the optimal drug, dose 
and timing is not known. One potential strategy is to provide women with nonsteroidal anti-inflammatory drugs 
(NSAIDs) and narcotic analgesics and advise them to first take NSAIDs once cramping starts and alternate the 
two medications if they continue to experience pain. 
 
Non-pharmacologic pain management 
In addition to medications, other methods that may help women manage pain during a medical abortion are 
thorough counseling, a supportive environment and applying a heating pad or hot water bottle to the lower 
abdomen. These methods are complementary but not adequate substitutes for pain management with 
medications.  
 
Quality of evidence 
There is limited trial data to establish the best regimen for pain control (Jackson & Kapp, 2011). Neither pain 
nor its treatment are systematically reported in clinical trials of medical abortion; where these data are 
reported, multiple regimens and treatment protocols are difficult to compare (Fiala et al., 2014). 
 
Young women 
Young women and nulliparous women have been shown to have higher analgesic requirements during medical 
abortion (Westhoff, Dasmahapatra, Winikoff, & Clarke, 2000; Westhoff, Dasmahapatra, & Schaff, 2000). 
Clinical Updates in Reproductive Health                        www.ipas.org/clinicalupdates 
 
                                                                          42 
 
Discussing pain control with young women and giving them the appropriate medications and instructions may 
be particularly important. 
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First-trimester medical abortion with mifepristone and 
misoprostol or misoprostol only: Prophylactic antibiotics 
 
Recommendation:  
Routine use of antibiotics is not recommended for women undergoing medical abortion. Women who 
have signs or symptoms of sexually transmitted infection at the time of medical abortion should be 
treated appropriately and medical abortion can be provided without delay. 
 
Strength of recommendation: Weak 
  
Quality of evidence: Very low 
  
Last reviewed: October 23, 2015 
 
Risk of infection   
The overall risk of infection found in prospective studies of medical abortion using mifepristone and a 
prostaglandin in the first trimester is approximately 0.01-0.5% (Chen & Creinin, 2015; Upadhyay et. al, 2015; 
Achilles & Reeves, 2011). Serious infections requiring hospitalization are very uncommon, with rates in large 
U.S. retrospective studies ranging from 0.03% to 0.09% (Fjerstad et al., 2009; Henderson, Hwang, Harper, & 
Stewart, 2005).   
  
Infectious mortality  
Nine cases of fatal Clostridium sepsis occurred in North America following mifepristone and misoprostol 
medical abortion (Cohen et al., 2007; Fischer et al., 2005; Meites, Zane, & Gould, 2010; Sinave, Le Templier, 
Blouin, Leveille, & Deland, 2002). One death from group A streptococcus has been reported in Australia and 
one death from Clostrium sordelli has been reported in Portugal (Reis et al., 2011) in women who used 
mifepristone and misoprostol. Although the deaths are concerning, the overall infections mortality rate related 
to medical abortion remains very low at 0.58 per 100,000 procedures (Meites et al., 2010). This rate is similar to 
the mortality rate after spontaneous abortion (Creinin, Blumenthal, & Shulman, 2006). 
 
Prophylactic antibiotics  
There have been no randomized controlled trials examining the effect of antibiotic prophylaxis on medical 
abortion outcomes (Low, Mueller, Van Vliet, & Kapp, 2012). A retrospective cohort study with historical 
controls from Planned Parenthood Federation of America showed that changing the route of administration of 
misoprostol from vaginal to buccal reduced the rate of serious infection from 0.093% to 0.025%, and routinely 
giving doxycycline twice a day for seven days starting on the day of mifepristone further reduced the rate to 
0.006% (Fjerstad et al., 2009). However, because the baseline rate of infection was so low, the number of 
women who had to take doxycycline to prevent a single serious infection was 5,000. Given the large number of 
women who would need to take antibiotics to prevent a single infection coupled with the expense and side 
effects of antibiotics, the American College of Obstetricians and Gynecologists (2009) the Society of Family 
Planning (Achilles & Reeves, 2011) and the World Health Organization (2012) do not recommend routine 
antibiotic use. In contrast, the Royal College of Obstetricians and Gynaecologists recommends routine antibiotic 
use with medical abortion procedures (2011). 
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Young women 
This recommendation is the same for young women.   
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First-trimester medical abortion with mifepristone and 
misoprostol or misoprostol only: Postabortion 
contraception 
 
Recommendation:  
 Hormonal methods including pills, patches, rings, injectables or implants may be started on the 
day of the first pill of medical abortion (WHO, 2012). 
 IUD insertion and sterilization can be performed when it is reasonably certain that a woman is 
no longer pregnant. 
 
Strength of recommendation: Strong 
  
Quality of evidence: Very low 
  
Last reviewed: October 27, 2015 
 
Fertility return 
On average, a woman will ovulate within 20 days of a medical abortion with mifepristone and misoprostol, but 
can ovulate in as little as eight days (Schreiber, Sober, Ratcliffe, & Creinin, 2011). Therefore, all women who 
wish to delay conception should leave the facility with an effective method of contraception. If a woman 
desires an intrauterine device (IUD) or sterilization, she should be counseled that these can be given at the 
same time as vacuum aspiration if she would prefer to leave the facility with her chosen method. If she still 
desires medical abortion, an interim method can be given and a follow-up visit made to provide IUD or 
sterilization when it is reasonably certain she is no longer pregnant.   
 
Contraceptive start  
Most forms of contraception (including pills, injectables and implants) may be started with the first pill of a 
medical abortion as long as there are no medical contraindications (WHO, 2015). IUDs may be inserted and 
sterilization performed as soon as it is reasonably certain that a woman is no longer pregnant (WHO, 2012).   
 
Contraceptive implants 
A prospective cohort study compared 57 women who had their implant placed on the day of mifepristone to 62 
women who had interval placement (Barros Pereira, Carvalho, & Graca, 2015). There was no difference in 
medical abortion efficacy between the two groups; continuation at six months was 74% in the same-day 
placement group, however only 16% in the delayed placement group returned and received their implant as 
planned.  
 
Intrauterine device 
IUDs inserted within 5-10 days of a successful medical abortion have low rates of expulsion and high 
continuation (Betstadt, Turok, Kapp, Feng, & Borgatta, 2011; Sääv, Stephansson, & Gemzell-Danielsson, 2012). 
IUD insertion one week after medical abortion has higher uptake and lower pregnancy rates than delayed 
insertion without an increased risk of expulsion (Shimoni, Davis, Ramos, Rosario, & Westhoff, 2011; Saav et al., 
2012).  
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Sterilization 
Sterilization may be performed as soon as it is reasonably certain that a woman is no longer pregnant and that 
a woman is not unduly influenced by the circumstances surrounding her abortion (WHO, 2012).   
 
Progestin-only injection 
One pilot study, which enrolled 20 women, administered depot medroxyprogesterone acetate within 15 
minutes of mifepristone administration (Sonalkar, McClusky, Hou & Borgatta, 2015. Completed abortion rate 
was 17/20 (85%), one participant had an ongoing pregnancy and two participants had incomplete abortions 
with continuing heavy bleeding 7 days after mifepristone. Ten participants discontinued the method after the 
first injection. 
 
Combined oral contraceptives  
Two randomized controlled trials of combined oral contraceptive pills started immediately after medical 
abortion compared to placebo showed that pills do not have a significant effect on the efficacy of medical 
abortion or the quantity or duration of blood loss (Tang, Gao, Cheng, Lee, & Ho, 1999; Tang, Xu, Cheng, Lee, & 
Ho, 2002). 
 
Barrier methods 
Barrier methods are safe to use at any time after a first-trimester medical abortion and can be used as a bridge 
to long-term methods or sterilization.   
 
Natural family planning 
Natural family planning, or the fertility-awareness method, should only be used after a woman has had at least 
one postabortion menses and only if she had regular menstrual cycles prior to the abortion (World Health 
Organization [WHO], 2015).   
  
Quality of the evidence 
There is limited clinical data to support the recommendation of starting hormonal methods on the same day as 
the first pill of medical abortion. This recommendation is based on expert opinion and pilot data (Sonalkar, Hou, 
& Borgatta, 2013; WHO, 2012). A woman's immediate need for reliable contraception after medical abortion, 
coupled with the risk that delayed contraceptive provision reduces uptake, strongly supports the 
recommendation to start these methods immediately. 
 
Young women 
The IUD for women under the age of 20 is classified by the WHO as category two, in which the benefits 
generally outweigh the risks. While risk is slightly increased due to higher rates of sexually transmitted 
infections and expulsion in this patient population, IUDs are still a safe, effective and recommended method for 
women under the age of 20. The WHO also classifies depot medroxyprogesterone acetate injection as a 
category two for women under 18 years of age, due to theoretical concerns about bone mineral density. 
Sterilization may be performed, but a young woman will need special precautions due to the increased risk of 
regret (WHO, 2015). 
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First-trimester medical abortion with mifepristone and 
misoprostol or misoprostol only: Postabortion IUD use 
 
Recommendation: 
An IUD can be placed within one week of medical abortion when it is reasonably certain that a woman is 
no longer pregnant.   
 
Strength of recommendation: Strong 
  
Quality of evidence: Very Low 
  
Last reviewed:  October 27, 2015 
Fertility return 
On average, a woman will ovulate within 20 days of a medical abortion with mifepristone and misoprostol, but  
can ovulate in as little as eight days (Schreiber, Sober, Ratcliffe, & Creinin, 2011). If a woman wants an 
intrauterine device (IUD) after medical abortion, she can use an interim method starting at the first visit and  
return to have the IUD placed when it is reasonably certain she is no longer pregnant. If she prefers to leave the 
facility with an IUD, she may be counseled about vacuum aspiration with immediate insertion as an alternative  
to medical abortion.  
 
Post-medical abortion IUD use 
IUDs may be placed as soon as it is reasonably certain that a woman is no longer pregnant following a medical 
abortion as long as there are no medical contraindications (World Health Organization [WHO], 2012). IUDs  
placed within 5-10 days of a successful medical abortion have low rates of expulsion and high continuation 
(Betstadt, Turok, Kapp, Feng, & Borgatta, 2011; Sääv, Stephansson, & Gemzell-Danielsson, 2012).  
IUD insertion one week after medical abortion has higher uptake and lower pregnancy rates than delayed  
insertion without an increased risk of expulsion (Shimoni, Davis, Ramos, Rosario, & Westhoff, 2011; Saav et al., 
2012).  
  
Young women 
The IUD for women under age 20 is classified by WHO as category two, in which the benefits generally outweigh 
the risks. While the risk may be slightly increased due to higher rates of sexually transmitted infections and 
expulsion in this patient population, IUDs are still a safe, effective and recommended method for women under 
age 20. 
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First-trimester medical abortion with mifepristone and 
misoprostol: Home use of medications 
 
Recommendation:  
 Women may take mifepristone in a facility or at home when it is convenient for them to start 
the abortion regimen.  
 Home use of misoprostol sublingually, vaginally or buccally in a combined regimen of 
mifepristone and misoprostol is a safe option for women with pregnancies below nine weeks 
(63 days) gestation (WHO, 2012). Home use of buccal misoprostol may be offered through 10 
weeks (70 days) gestation in a combined mifepristone-misoprostol regimen (Winikoff, 2012). 
 
Strength of recommendation: Strong 
 
Quality of evidence: 
             Up to 63 days: High 
            64-70 days: Moderate 
 
Last reviewed: October 21, 2015 
 
Background 
Traditionally, providers have given mifepristone to women to take in a facility to start the abortion regimen.  
Then 24-48 hours later, women may take misoprostol in a medical facility, their own home or another safe 
location. Because of women’s individual preferences for privacy, support, and timing, they should have options 
about the location of mifepristone and misoprostol use. 
 
Home use of mifepristone 
Two prospective, nonrandomized multicenter cohort studies conducted in the US, which together included 701 
women, showed that between a third and a half of women offered home or facility use of mifepristone chose 
home use (Swica et al., 2012; Chong et al., 2015).  Women who used mifepristone at home had similar success 
rates and need for telephone or emergency room support as women who took mifepristone in the clinic, and 
they were highly satisfied. In similar studies conducted in Azerbaijan (Louie et al., 2014) and Nepal (Conkling et 
al., 2015), 74% and 72% of women, respectively, chose home use, citing presence of their partner and a more 
private experience as the most common reasons. Abortion success rates were the same in the home use and 
clinic use groups. If women choose home use of mifepristone when they are using a combined medical abortion 
regimen, they should schedule the medications within one week of their clinic visit as long as it is under the 
gestational age limit.  
  
Home use of misoprostol up to 63 days 
A systematic review of nine prospective comparative cohort studies with 4,522 women up to 56 days gestation 
showed that complete abortion rates and adverse event rates were the same for home- or facility-based 
misoprostol use (Ngo, Park, Shakur, & Free, 2011) as part of a mifepristone-misoprostol regimen. Women in the 
included studies found home use as acceptable as clinic use. Large observational studies up to 59 days (Fjerstad 
et al., 2009) and 63 days (Goldstone, Michelson, & Williamson, 2012; Lokeland et al., 2014; Louie et al., 2014; 
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Raghavan et al., 2013; Gatter, Cleland, & Nucatola, 2015) also confirm the safety and efficacy of home use of 
misoprostol. The World Health Organization (2012), American College of Obstetricians and Gynecologists (2005) 
and Royal College of Obstetricians and Gynaecologists (2011) recommend home use of misoprostol up to 63 
days.       
 
Home use of misoprostol from 64-70 days  
A multicenter study of 729 women in the United States comparing a single dose of buccal misoprostol 800mcg 
at home from 57-63 days and from 64-70 days as part of a mifepristone-misoprostol regimen showed no 
difference in success rates, ongoing pregnancy or adverse events (Winikoff et al., 2012). Offering women up to 
10 weeks gestation a single dose of buccal misoprostol at home rather than repeat doses of misoprostol in a 
facility may be appropriate in some settings (Boersma, Meyboom-de Jong, & Kleiverda, 2011; Winikoff et al., 
2012). This study used ultrasound to determine gestational age for eligibility. Programs using this approach in 
different conditions should monitor their results to ensure success in their settings. 
  
A prospective, open-label trial conducted in Ukraine, Georgia, India and Tunisia compared outcomes of 703 
women who received mifepristone followed by 400mcg of at-home sublingual misoprostol for pregnancies of 
57-63 days or 64-70 days gestation (Bracken et al., 2014). Success rates and ongoing pregnancy rates did not 
differ between groups, although women in the later gestational age group were more likely to receive an 
additional dose of misoprostol or require intervention for bleeding.  
 
Young women 
This recommendation is the same for young women.  
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First-trimester medical abortion with mifepristone and 
misoprostol or misoprostol only: Ultrasound findings at 
follow-up 
 
Recommendation:  
Ultrasound is not necessary for medical abortion follow-up and may lead to unnecessary intervention. 
If clinicians choose to use ultrasound, the only ultrasound finding that requires intervention is an 
ongoing viable pregnancy.     
 
Strength of recommendation: Strong 
  
Quality of evidence: Moderate 
  
Last reviewed: October 24, 2015 
 
Background 
Ultrasound is not necessary to provide abortion care (WHO, 2012) but may be common in some settings. 
Ultrasound for follow-up after medical abortion has diagnostic limitations. Except for the rare case of an 
ongoing viable pregnancy, intervention after a medical abortion should be based on clinical symptoms and not 
ultrasound findings.     
  
Findings 
Endometrial thickening: After a successful medical abortion, the endometrium can have varying thickness and 
have a complex or heterogeneous appearance. 
 
 
Endometrial thickening 
 
Multiple retrospective and prospective cohort studies have shown that endometrial thickness has a wide range 
in women after medical abortion, with significant overlap between women with successful and failed medical 
abortion (Cowett, Cohen, Lichtenberg, & Stika, 2004; Markovitch, Tepper, Klein, Fishman, & Aviram, 2006; 
Parashar, Iversen, Midbøe, Myking, & Bjørge, 2007; Rørbye, Nørgaard, & Nilas, 2004; Tzeng, Hwang, Au, & 
Chien, 2013). In a pooled analysis of 2,208 women one week after medical abortion, once women with a 
persistent gestational sac were excluded, the average endometrial thickness was 10.9mm in women who did 
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not require more intervention and 14.5mm in 30 women who did require intervention (Reeves, Fox, Lohr, & 
Creinin, 2009). Although the average endometrial thickness in women who require intervention tends to be 
higher, because of the range and overlap between successful and unsuccessful abortion, no study has found 
that there is a thickness above which a diagnosis of unsuccessful medical abortion can be made. The decision of 
whether to intervene should be made on clinical signs and symptoms, such as ongoing or heavy bleeding, 
rather than ultrasound findings.  
 
Persistent gestational sac: A persistent gestational sac, in which the sac is present but there is no viable 
embryonic tissue, occurs in less than 1% of medical abortions with the recommended mifepristone and 
misoprostol regimen (Creinin et al., 2004; Creinin et al., 2007; Winikoff et al., 2008). A persistent gestational sac 
is not a viable pregnancy and may be managed with aspiration, a second dose of misoprostol or expectant 
management according to a woman’s preference. In a study of women with a persistent gestational sac within 
11 days of medical abortion, a second dose of misoprostol was found to lead to expulsion of a nonviable sac in 
69% of women (Reeves, Kudva, & Creinin, 2008).    
 
 
Persistent gestational sac 
 
Ongoing viable pregnancy: An ongoing pregnancy, in which the sac and an embryo with cardiac activity are 
present, occurs in less than 1% of medical abortions with the recommended mifepristone and misoprostol 
regimen (Von Hertzen et al., 2009; Winikoff et al., 2008). Some women will be able to identify this outcome 
without ultrasound due to lack of bleeding or continued pregnancy symptoms. A woman with an ongoing 
pregnancy should be offered uterine evacuation as soon as possible. She may have vacuum aspiration or a 
second dose of misoprostol may be considered. The success rate of misoprostol after failed medical abortion is 
36% (Reeves, Kudva, & Creinin, 2008; WHO, 2012). If a woman chooses a second dose of misoprostol, she must 
be followed to see if it is successful.   
  
Young women 
This recommendation is the same for young women. 
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First-trimester medical abortion with mifepristone and 
misoprostol or misoprostol only: Risk of fetal malformations 
 
Recommendation:  
Exposure to mifepristone alone has not been shown to cause fetal malformations. Exposure to 
misoprostol, whether in a combined or misoprostol-only regimen, carries a small increased risk of 
malformations if the woman has an ongoing pregnancy and decides not to terminate. Women with an 
ongoing pregnancy after using misoprostol should be counseled about the risk if they choose to carry 
the pregnancy to term. 
 
Strength of recommendation: Strong 
 
Quality of evidence:  
Mifepristone: Very low 
Misoprostol: Moderate 
 
Last reviewed:  October 24, 2015 
 
Background 
The expected rate of fetal malformations in the general population is approximately 3% (Dolk, Loane, & Garne, 
2010). Exposure to certain medications, infections, radiation or drugs of abuse during embryonic or fetal 
development may result in an increased risk of malformations if the pregnancy continues.  
  
Mifepristone  
Mifepristone exposure may occur if a woman changes her mind and does not take misoprostol after taking 
mifepristone. Data on continuing pregnancy after mifepristone exposure without misoprostol are limited. The 
largest prospective study of 46 women continuing a pregnancy after mifepristone only resulted in eight 
miscarriages and two major malformations in the pregnancies that continued (5.3%). Both malformations were 
not thought to be related to mifepristone exposure but may have been a result of other medical conditions 
(Bernard et al., 2013).    
  
Misoprostol 
The association between misoprostol and congenital anomalies is better established. Case reports, cohort 
studies (da Silva Dal Pizzol, Tierling, Schüler-Faccin, Sanseverino, & Mengue, 2005; Vauzelle, Beghin, Cournot, & 
Elefant, 2013) and case-control studies (da Silva Dal Pizzol, Knop, & Mengue, 2006) show that the incidence of 
malformations peaks if misoprostol is used between 5-8 weeks after a woman's last menstrual period (LMP) 
and is not associated with anomalies after 13 weeks LMP (Philip, Shannon, & Winikoff, 2002). The most typical 
malformations associated with misoprostol use are Mӧbius sequence, a rare disorder of cranial nerve palsies 
associated with limb anomalies and craniofacial defects, and terminal transverse limb defects (da Silva Dal 
Pizzol et al., 2006). Although not clearly established, the proposed mechanism is vascular disruption from 
uterine contractions leading to disordered fetal development (Gonzalez et al., 2005; Shepard, 1995). 
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A systematic review of four case-control studies with 4,899 cases of congenital anomalies and 5,742 controls 
showed an increased rate of misoprostol exposure in cases with anomalies (da Silva Dal Pizzol et al., 2006). 
Misoprostol exposure was 25 times more likely in cases with Mӧbius sequence and 12 times more likely with 
terminal transverse limb defects. A prospective follow-up study comparing women who used misoprostol 
before 12 weeks of pregnancy to women who used antihistamines showed that the rate of fetal malformations 
was higher in the 236 pregnancies exposed to misoprostol (4%) than in 255 controls (1.8%) although the finding 
was not statistically significant (Vauzelle et al., 2013). Three malformations (2%) in the misoprostol group were 
consistent with misoprostol-related anomalies.   
 
Although the rate of misoprostol exposure is higher in children born with characteristic defects such as Mӧbius 
sequence, the anomalies are so rare that the overall risk is low that a woman who takes misoprostol in the first 
trimester and carries a pregnancy to term will have a child born with a malformation related to misoprostol 
exposure. A woman’s risk of a malformation related to misoprostol exposure is less than 10 per 1,000 
exposures (Philip et al., 2002).       
  
Young women 
This recommendation is the same for young women. 
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Misoprostol product quality 
 
Recommendation:  
Because different misoprostol products have varying quality and can degrade over time, providers 
should track medical abortion success rates to ensure that they are using an effective product. 
Providers should store misoprostol in a cool dry place. 
 
Strength of recommendation: Strong 
 
Quality of evidence: Low 
  
Last reviewed: October 21, 2015 
 
Background  
With the increasing use of misoprostol for reproductive health indications, there are concerns about the quality 
of misoprostol products. If misoprostol degrades, it may lead to decreased success rates with medical abortion 
and unsuccessful treatment of incomplete abortion and postpartum hemorrhage. A technical memo distributed 
by Pathfinder International reported that Misotac, a brand of misoprostol manufactured by Sigma, was recalled 
because batches of the medicine had degraded and no longer contained a sufficient amount of the active 
ingredient (Pathfinder, 2011).   
  
Differences in quality related to manufacturing  
There are at least 30-40 manufacturers of misoprostol worldwide and some manufacturers subcontract, which 
makes it difficult to enforce Good Manufacturing Practice and ensure quality across all brands (Hall, 2011). 
Although misoprostol is thought to be stable at normal room temperature, the active pharmaceutical 
ingredient (misoprostol oil) used in manufacturing must be stored below -20°C. Thus, exposure to heat and 
humidity during manufacturing, packaging and storage may compromise the quality of misoprostol (Cayman 
Chemical, 2012). 
 
A 2011 study analyzed 76 misoprostol samples from countries all over the world (Hall, 2011). Two types of 
misoprostol contained the drug diclofenac and were excluded from analysis. When the remaining 74 samples 
were tested for content and purity, eight of the 200mcg tablets contained less than 40mcg of active ingredient. 
The analysis found that three factors influenced misoprostol integrity: 1) impact of moisture at all stages 2) 
manufacture and quality of the active pharmaceutical ingredient and 3) packaging. Misoprostol that was 
packaged in double-aluminum blister packs (aluminum on top and bottom) was found to retain the most active 
ingredient. 
 
Misoprostol brands that have been approved by the European Union or the United States Food and Drug 
Administration are known to conform to Good Manufacturing Practice and are high quality. The United Nations 
Population Fund (UNFPA) has added misoprostol to its list of commodities which are available through long-
term agreement. UNFPA is committed to procuring products which meet specified requirements and standards, 
according to internationally recognized quality standards.   
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Clinic use and storage 
Even misoprostol manufactured in high-quality conditions and packaged well can become inactive if it is 
shipped or stored in conditions that expose it to heat or humidity for prolonged periods of time. There have not 
been large field studies on the stability of misoprostol in tropical climates, but laboratory studies show that 
misoprostol is less stable when exposed to moisture or heat (Chu, Wang, Pang, & Rogers, 2007; WHO, 2009). 
Even in normal room temperature conditions (25°C and 60% humidity), when providers cut blister packs to 
distribute tablets, if the packaging on the remaining stored tablets is inadvertently opened, the tablets’ potency 
degrades within 48 hours and continues to degrade over time (Berard et al., 2014).  
 
Quality assurance 
If providers notice a sudden decrease in medical abortion success rates from expected baseline, they should 
discard the lot of misoprostol being used and start a new lot. Providers should consult with each other to 
determine which local misoprostol brands are most effective. Store misoprostol in dry conditions at 
temperatures at or below 25°C (77°F) (Pfizer, 2002).   
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First-trimester medical abortion with mifepristone and 
misoprostol: Success and complication rates 
 
Key information:  
A combined regimen of mifepristone and misoprostol is effective and safe, with success rates of over 
95% and complication rates of less than 1%. 
 
Quality of evidence: High 
  
Last reviewed: October 26, 2015 
 
Background 
The most robust data on safety and efficacy of medical abortion come from large studies done in multiple high-
volume health centers with experienced providers using ultrasound (Gatter, Cleland, & Nucatola, 2015; Cleland, 
Creinin, Nucatola, Nshom, & Trussell, 2013; Goldstone, Michelson, & Williamson, 2012). Settings with lower 
volume and new or inexperienced providers may have different results.  
 
Success of medical abortion 
Medical abortion success is defined as a complete abortion that needs no further intervention. A 2015 
systematic review reported data from 20 studies with a total of 33,846 women undergoing medical abortion 
through 70 days gestation (Chen & Creinin, 2015). The overall efficacy of mifepristone followed by buccal 
misoprostol was 96.7% and the continuing pregnancy rate was 0.8% in the approximately 33,000 pregnancies 
through 63 days gestation. The efficacy rate for the 332 women with pregnancies between 64-70 days gestation 
was 93.1%, and the continuing pregnancy rate was 2.9%.  
 
Complication rates 
A review of 233,815 medical abortions under nine weeks done at private clinics in the United States from 2009-
2010 with mifepristone and buccal misoprostol found a complication rate of 0.65% (Cleland et al., 2013). In this 
study, complications included both serious outcomes—such as ongoing pregnancy or an unrecognized ectopic 
pregnancy—and serious adverse events such as transfer, hospitalization, intravenous antibiotics, blood 
transfusion and death; the need for an outpatient repeat procedure was not tracked or included in the 
complication rate. The most common complication was ongoing pregnancy affecting 0.5% of the study 
population. The rate of serious adverse events was 0.16%. There was only one death in a woman with an 
undiagnosed ectopic pregnancy, thereby producing a mortality rate of 0.4 per 100,000 medical abortion 
procedures. 
 
A large retrospective U.S. cohort study of 11,319 first-trimester medical abortions evaluated all complications 
from abortions provided in the state of California from 2009-2010 (Upadhyay et al., 2015). Uniquely, 
researchers were able to assess complications arising at the time of the abortion, as well as complications 
diagnosed when patients sought additional care from sites other than the site where the abortion was 
provided, such as emergency departments. The overall rate of complications during the six weeks following 
medical abortion was 5.2%; only 0.3% were major complications—defined as requiring hospitalization, surgery 
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or blood transfusion. Complications included incomplete abortion (0.87%), failed abortion (0.13%), hemorrhage 
(0.14%), infection (0.23%) and undetermined/other (3.82%).  
 
Young women 
Young women and adolescents have similar or higher success rates compared to older women and similar or 
lower complication rates (Niinimäki et al., 2011).  
 
Complications by study 
 Goldstone, 2012 Cleland, 2013 Gatter, 2015 
Number of women 13,345 233,805 13,373 
 
Location / Organization 
 
MSI Australia Planned Parenthood USA Planned Parenthood USA 
Time period 
 
2009-2011 2009-2010 2006-2011 
Incomplete abortion 
requiring aspiration 
2.9% Not reported 2.3% 
Unrecognized ectopic 
pregnancy 
Not reported 0.007% Not reported 
Ongoing pregnancy 
 
0.6% 0.5% 0.5% 
Transfusion 
 
0.08% 0.05% 0.03% 
Infection 
 
0.03% 0.02% 0.01% 
Death 0.007% (1 death from 
infection) 
0.0004% (1 death from 
unrecognized ectopic 
pregnancy) 
No deaths 
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First-trimester medical abortion with mifepristone and 
misoprostol: Recommended regimen 
 
Key information:  
 Up to nine weeks gestation: Mifepristone 200mg orally followed 24-48 hours later by 
misoprostol 800mcg buccally, sublingually or vaginally. 
 9-10 weeks gestation: Mifepristone 200mg orally followed 24-48 hours later by misoprostol 
800mcg buccally.   
 10-13 weeks gestation: Mifepristone 200mg orally followed 36-48 hours later by misoprostol 
800mcg vaginally then 400mcg vaginally or sublingually every three hours for a maximum of five 
doses of misoprostol. 
 
Strength of recommendation: Strong 
  
Quality of evidence:  
 Up to nine weeks gestation: High 
 9-10 weeks gestation: Moderate 
 10-13 weeks gestation: Low 
  
Last reviewed: October 28, 2015 
 
Up to nine weeks 
Multiple randomized controlled clinical trials have shown that the combination of mifepristone and misoprostol  
is an effective medical abortion regimen with success rates ranging from 95-98% (Chen & Creinin, 2015; Kulier et 
al., 2011; Raymond, Shannon, Weaver, & Winikoff, 2012). Vaginal, buccal and sublingual misoprostol are more 
effective than oral misoprostol (Kulier et al., 2011). Buccal dosing (Middleton et al., 2005) and sublingual dosing 
(Tang, Lau, Ng, Lee, & Ho, 2003; von Hertzen et al., 2010) have higher rates of gastrointestinal side effects than 
vaginal dosing. Sublingual dosing is associated with more side effects than buccal dosing (Chai, Wong, & Ho, 
2013). In some settings, buccal or sublingual dosing may be preferred due to infection prevention (Fjerstad et al., 
2009), legal restrictions or a woman’s preference. 
  
Although effective, 400mcg of sublingual misoprostol (instead of the recommended 800mcg) following 
mifepristone is associated with higher rates of incomplete abortion and ongoing pregnancy (von Hertzen et al., 
2010; Raghavan et al., 2013; Bracken et al., 2014), and therefore should not be substituted for the 800mcg dose. 
Lower doses of mifepristone and misoprostol for use in very early pregnancy are under investigation (Li et al., 
2015). 
 
9-10 weeks   
Rapidly evolving evidence confirms the safety and efficacy of medical abortion between 9-10 weeks gestation. A 
2015 review reports data from six medical abortion studies which included 928 women with gestations between 
64-70 days and 1,163 with gestations from 57-63 days (Abbas, Chong, & Raymond, 2015). Although regimens 
varied between studies—200mg mifepristone followed by 800mcg buccal, 800mcg vaginal or 400mcg sublingual 
misoprostol—there was no difference in success rates between the two gestational groups (93.9% at 57-63 days 
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compared to 92.3% at 64-70 days). Further, there were no differences in serious adverse events, such as hospital 
admissions or transfers, between the groups (0.7% and 0.5% respectively).   
  
10-13 weeks 
A cohort study of 1,076 women showed a combination of mifepristone and repeat doses of misoprostol is safe 
and effective between 9-13 weeks (Hamoda, Ashok, Flett, & Templeton, 2005). All women took misoprostol in  
the health facility. The success rate for this regimen was high at 95.8%, with a low rate of serious adverse events. 
Repeat dosing of misoprostol has been shown to increase the efficacy of second-trimester medical abortion and 
may be used for women in the late first trimester (Wildschut et al., 2011).   
  
Young women 
This recommendation is the same for young women. 
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First-trimester medical abortion with mifepristone and 
misoprostol: Contraindications and precautions 
 
Key information:  
Contraindications:  
 Previous allergic reaction to one of the drugs involved 
 Inherited porphyria 
 Chronic adrenal failure 
 Known or suspected ectopic pregnancy 
 
Precautions: 
 IUD in place. Evaluate for the presence of ectopic pregnancy. If none, remove the IUD. 
 
 Severe uncontrolled asthma or long-term corticosteroid therapy. No evidence exists regarding 
use of mifepristone in steroid-dependent women. Providers must use clinical judgment if no 
other alternatives to safe abortion exist. Increase steroid dose for 3-4 days and monitor the 
woman very closely. Conditions such as poorly controlled asthma may still be worsened. 
 
 Severe/unstable health problems including but not limited to hemorrhagic disorders, heart 
disease, and severe anemia. No evidence exists on the use of medical abortion in women with 
hemorrhagic disorder, heart disease, severe anemia or severe/unstable health problems. 
Whether to provide medical abortion to women with these conditions will depend on the 
available options for safe abortion care, referrals, and clinical judgment. If medical abortion is 
provided, it should be given under close observation. 
 
Strength of recommendation: Moderate 
  
Quality of evidence: Graded for each specific contraindication or precaution below 
  
Last reviewed: October 26, 2015 
 
Definitions 
Contraindications: If a woman has these specific conditions, under no circumstances should she be offered 
medical abortion with mifepristone and misoprostol. Vacuum aspiration should be considered or she should be 
referred to a facility where she can be offered alternate care. 
  
Precautions:  If a woman has these specific conditions, medical abortion with mifepristone and misoprostol has 
higher risks than normal. The risks, benefits and alternatives to medical abortion must be considered. Medical 
abortion provision may require a higher degree of clinical judgment, skill and monitoring. Referral to a higher-
level facility may be appropriate.  
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Quality of evidence: 
 
Contraindications 
Previous allergic reaction to one of the drugs involved: Allergic reactions have been reported after the use of 
mifepristone and misoprostol (Hauseknecht, 2003; Schoen, 2014). Quality of evidence: High 
   
Inherited porphyria: Porphyrias are rare metabolic disorders in which enzymes in heme are deficient. 
Theoretically, mifepristone could exacerbate porphyria (Ventura et al., 2009). Quality of evidence: Low. No  
human studies exist, but animal models exhibit the effect of mifepristone (Cable et al., 1994). 
  
Chronic adrenal failure: Mifepristone is a glucocorticoid receptor antagonist (Spitz & Bardin, 1993). Mifepristone 
blocks negative feedback mechanisms that control cortisol secretion. In women with adrenal insufficiency on 
long-term corticosteroid therapy, mifepristone exposure may exacerbate the underlying condition (Sitruk-Ware  
& Spitz, 2003). Quality of evidence: Low. There are no data on mifepristone use in pregnant women with adrenal 
insufficiency, but there is experimental and animal data to support the recommendation. 
  
Known or suspected ectopic pregnancy: Mifepristone and misoprostol do not treat ectopic pregnancy, and use of 
the medications may delay diagnosis of this life-threatening condition. Quality of evidence: High 
  
Precautions 
IUD in place: A woman who is pregnant with an IUD in place is at significantly elevated risk of ectopic pregnancy 
(Barnhart, 2009). The woman must be evaluated for the presence of ectopic pregnancy. If negative, the IUD 
should be removed before starting medical abortion due to the theoretical risk of uterine perforation from 
contractions during medical abortion and the potential risk of infection (Danco, 2010; Davey, 2006). Quality of 
evidence: Low. There are no studies to verify whether having an IUD in place poses actual risks during medical 
abortion. 
 
Severe uncontrolled asthma or long-term corticosteroid therapy: Mifepristone is a glucocorticoid receptor 
antagonist (Spitz & Bardin, 1993). Mifepristone blocks negative feedback mechanisms that control cortisol 
secretion. In women on long-term corticosteroid therapy for severe or uncontrolled asthma, mifepristone 
exposure may exacerbate the underlying condition (Sitruk-Ware & Spitz, 2003). There are no direct studies of 
medical abortion among women on corticosteroid treatment, but one review suggested that increasing the dose 
of the steroid medications can counteract the cortisol blunting effect of mifepristone (Davey, 2006). For most 
conditions, adjusting the dose of corticosteroid medications after mifepristone administration and careful 
monitoring may allow for medical abortion.  
 
Medical abortion in asthmatic women requiring systemic corticosteroids has not been studied. One review 
suggests using a high level of caution when giving mifepristone to such women and only doing so if the asthma is 
well controlled (Davey, 2006). The glucocorticoid dose should be increased for several days before and after 
mifepristone. Other experts recommend that women with severe, poorly controlled asthma who are on  
long-term corticosteroids not take mifepristone due to the life-threatening nature of acute asthma exacerbation 
(Christin-Maitre et al., 2000; Creinin & Gemzell Danielsson, 2009; Sitruk-Ware, 2006). Giving mifepristone to  
such women risks exacerbating asthma. 
 
Inhaled corticosteroids for asthma are not systemically absorbed and are not a contraindication to mifepristone. 
Some experts recommend that mifepristone and misoprostol should be available to women with asthma as long 
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as they are not on long-term systemic steroids (Creinin & Gemzell Danielsson, 2009). Quality of evidence: 
Moderate 
 
Severe medical problems: Medical abortion studies tend to exclude women with severe anemia or severe  
medical problems (Christin-Maitre et al., 2000; Sitruk-Ware & Spitz, 2003). Whether to provide medical abortion 
to women with these conditions will depend on clinical judgment, monitoring and options available for safe 
abortion care. Quality of evidence: Low  
   
Young women 
This information is the same for young women. 
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First-trimester medical abortion with mifepristone and 
misoprostol: Confirmation of success 
 
Recommendation: 
 Most women can confirm a successful medical abortion with mifepristone and misoprostol. 
 Providers may perform a clinical assessment to assist in the confirmation of successful abortion. 
 Ultrasound or other testing is needed only in cases where the diagnosis is unclear. 
Strength of recommendation: Strong 
 
Quality of evidence: Moderate 
 
Last reviewed: October 31, 2015 
 
Woman’s assessment of successful abortion 
Evidence indicates that women can accurately determine when their medical abortion is successful—that is 
whether pregnancy expulsion has occurred. In studies comparing women’s assessments of expulsion to those 
made by clinicians (Cameron et al., 2012; Perriera et al., 2010; Clark et al., 2010; Rossi, 2004) and by ultrasound 
(Rossi, 2004), particularly when standardized questions are used (Perriera et al., 2010; Clark et al., 2010; 
Cameron et al., 2012), women have repeatedly proven themselves to be nearly as accurate as both. The World 
Health Organization (WHO) has determined that routine follow-up after medical abortion with mifepristone 
and misoprostol in not required (2012). 
 
Clinical assessment 
Providers may help confirm successful abortion at a follow-up visit by reviewing a patient history and 
performing a bimanual exam if indicated. In three studies comparing clinical assessment to ultrasound (Perreira 
et al., 2010; Rossi et al., 2004; Pymar et al., 2001), clinicians were able to determine pregnancy expulsion with 
high levels of accuracy.  
 
Ultrasound 
Ultrasound can be used to confirm successful abortion but is not necessary and can add to the cost and 
complexity of medical abortion (Kaneshiro, Edelman, Sneeringer, & Ponce de Leon, 2011). Ultrasound is helpful 
in cases where there is doubt about whether the abortion has been successful. 
 
Serum pregnancy testing 
Serum pregnancy testing has been used as an alternative to ultrasound to diagnose successful medical abortion 
and compares favorably to ultrasound in reducing interventions at the time of follow-up (Clark, Panton, Hann, 
& Gold, 2007; Dayananda, Maurer, Fortin, & Goldberg, 2013; Fiala, Safar, Bygdeman, & Gemzell-Danielsson, 
2003). Serum pregnancy testing is only useful when a pre-treatment hCG has been obtained for comparison. 
The utility of serum pregnancy testing is low in areas where access to laboratory testing is limited. 
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Urine pregnancy testing 
A negative urine pregnancy test is usually reassuring that an abortion has been successful; however, it is rare, 
but does occur, that a pregnancy test is negative but a woman is still pregnant (false negative). Both high-
sensitivity and low-sensitivity urine pregnancy tests can have positive results even when the medical abortion 
has been successful (false positive) (Cameron et al., 2012; Clark et al., 2010; Godfrey, Anderson, Fielding, Meyn, 
& Creinin, 2007; Perriera et al., 2010). Use of low-sensitivity (Iyengar et al., 2015; Cameron et al., 2012)and 
semi-quantitative (Platais et al., 2015; Oppegaard et al., 2015; Ngoc et al., 2014; Blum et al., 2012; Lynd et al., 
2013) urine pregnancy tests to confirm success of medical abortion is an area of active research. 
 
Young women 
This recommendation is the same for young women. 
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First-trimester medical abortion with misoprostol only: 
Recommended regimen 
 
Recommended regimen up to 13 weeks: 
 
Dose Route Timing 
Misoprostol 800mcg (4 200mcg pills) Vaginal Every 3-12 hours for a 
maximum of 3 doses 
Misoprostol 800mcg (4 200mcg pills) Sublingual Every 3 hours for a maximum 
of 3 doses 
 
Strength of recommendation:  Strong 
 
Quality of evidence: 
 Up to nine weeks: Moderate 
 9-13 weeks: Low 
 
Last reviewed: October 24, 2015 
 
Success of misoprostol-only medical abortion  
The success rate of medical abortion with misoprostol only is around 85% (von Hertzen et al., 2007). 
Misoprostol-only treatment should be considered when mifepristone is not available. In general, misoprostol-
only regimens have higher rates of success at lower gestational age (von Hertzen et al., 2007; Zikopoulos et al., 
2002), with higher numbers of doses (Carbonell, Varela, Velazco, Tanda, & Sanchez, 1999) and with a longer 
time period before provider follow-up to confirm abortion success (Bugalho, Mocumbi, Faundes, & David, 
2000). However, women’s satisfaction decreases the longer the abortion process lasts (Ngai, Tang, Chan, & Ho, 
2000).   
 
Misoprostol-only abortion up to nine weeks 
The only multicenter randomized controlled trial to compare different misoprostol-only dosing intervals 
showed that complete abortion rates are equivalent when misoprostol is given vaginally every 3-12 hours or 
sublingually every three hours for three doses. Sublingual dosing had a higher incidence of side effects than 
vaginal dosing (von Hertzen et al., 2007).  
 
Misoprostol-only abortion between 9-13 weeks  
There is scant evidence to recommend an appropriate dosing regimen between 9-13 weeks. The only direct 
evidence for this gestational range comes from three small cohort studies where misoprostol 800mcg was given 
vaginally every 12 or 24 hours for up to three doses (Carbonell Esteve et al., 1998; Carbonell et al., 1999; 
Carbonell et al., 2001). However, there is strong evidence in randomized controlled trials of misoprostol-only in 
the early second trimester that support using a vaginal dosing interval of every three hours over 13 weeks (von 
Hertzen et al., 2009). Given the evidence supporting repeat doses of sublingual or vaginal misoprostol below 
nine and above 13 weeks, the evidence-based regimen for below nine weeks may be used between 9-13 weeks. 
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Young women   
This recommendation is the same for young women.    
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First-trimester medical abortion with misoprostol only: 
Contraindications and precautions 
 
Recommendation:  
Contraindications: 
 Previous allergic reaction to misoprostol 
 Known or suspected ectopic pregnancy 
 
Precautions: 
 Intrauterine device (IUD) in place. Evaluate for the presence of ectopic pregnancy. If none, 
remove the IUD.  
 
 Severe/unstable health problems including but not limited to hemorrhagic disorders, heart 
disease and severe anemia. No evidence exists on the use of medical abortion in women with 
hemorrhagic disorder, heart disease, severe anemia or severe/unstable health problems. 
Whether to provide medical abortion to women with these conditions will depend on the 
available options for safe abortion care, referrals, and clinical judgment. If medical abortion is 
given, it should be under close observation.  
 
Strength of recommendation: Moderate  
  
Quality of evidence: Graded for each specific contraindication or precaution below. 
  
Last reviewed: October 28, 2015 
 
Definitions 
Contraindications: If a woman has these specific conditions, under no circumstances should she be offered 
medical abortion with misoprostol only. Vacuum aspiration should be considered or she should be referred to a 
facility where she can be offered alternate care. 
 
Precautions: If a woman has these specific conditions, medical abortion with misoprostol only has higher risks 
than normal. The risks, benefits and alternatives to medical abortion must be considered. Medical abortion 
provision may require a higher degree of clinical judgment, skill and monitoring. Referral to a higher-level 
facility may be appropriate.  
  
Quality of evidence: 
 
Contraindications 
Previous allergic reaction to misoprostol: Very rare allergic reactions have been reported after the use of 
misoprostol (Schoen, 2014). Quality of evidence: Low  
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Known or suspected ectopic pregnancy: Misoprostol does not treat ectopic pregnancy and use of the 
medications may delay diagnosis of this life-threatening condition. Quality of evidence: High 
 
Precautions 
IUD in place: A woman who is pregnant with an IUD in place is at significantly elevated risk of ectopic pregnancy 
(Barnhart, 2009). The woman must be evaluated for the presence of ectopic pregnancy. If negative, the IUD 
should be removed before starting medical abortion due to the theoretical risk of uterine perforation from 
contractions during medical abortion and the potential risk of infection (Danco, 2010; Davey, 2006). There are 
no studies to verify whether having an IUD in place poses actual risks during medical abortion. Quality of 
evidence: Low 
  
Severe/unstable health problems: Medical abortion studies tend to exclude women with severe anemia or 
severe medical problems (Christin-Maitre, Bouchard, & Spitz, 2000; Sitruk-Ware, 2006) Whether to provide 
medical abortion to women with these conditions will depend on clinical judgment, monitoring and options 
available for safe abortion care. Quality of evidence: Low  
  
Young women 
This recommendation is the same for young women. 
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Who has second-trimester abortions? 
Key information:  
Women who present for abortion in the second trimester of pregnancy tend to be younger, detect their 
pregnancy later, feel ambivalent about the abortion decision, and/or have financial and logistical 
barriers to care. Additionally, women may have medical or fetal indications for an abortion that are not 
apparent until the second trimester. Reasons for presenting in the second trimester appear similar 
across countries and cultures. Second-trimester abortion disproportionately affects more underserved 
women.  
 
Quality of evidence: High 
Last reviewed: May 28, 2015 
Background 
While second-trimester abortions are a small percentage (around 10%) of all abortions worldwide, these 
abortions are responsible for the majority of major complications (Harris & Grossman, 2011; Loeber & Wijsen, 
2008; Pazol, Creanga, Burley, & Jamieson, 2014). In restrictive settings where abortion complications are 
prevalent, second-trimester presentation for postabortion care is common. In Cambodia, 17% of women needing 
postabortion care present in the second trimester, 38% in Ethiopia, and 41% in Kenya (African Population and 
Health Research Center, Ministry of Health Kenya, Ipas Kenya, & Guttmacher Institute, 2013; Fetters, Vonthanak, 
Picardo, & Rathavy, 2008; Gebreselassie et al., 2010).  
 
Why do women need second-trimester abortions?  
Young age: Young women are disproportionately likely to seek abortion in the second trimester. In the United 
States, 9% of all women who present for abortions do so in the second trimester, but the rate is 21.7% for girls 
younger than age 15 and 12.4% for adolescents ages 15-19 (Pazol et al., 2014). Smaller case-control and cohort 
studies in the United States, Singapore, Ethiopia, India, and Nepal find young age is a risk factor for second-
trimester presentation (Bonnen, Tuijje, & Rasch, 2014; Foster & Kimport, 2013; Lim, Wong, Yong, & Singh, 2012; 
Sowmini, 2013).    
 
Late detection of pregnancy: A common risk factor in all studies of women presenting for second-trimester 
abortion is late recognition of pregnancy. Absence of pregnancy signs and symptoms, menstrual irregularity, 
contraceptive use, or amenorrhea after recent pregnancy can mask physical signs of pregnancy and delay 
pregnancy diagnosis (Drey et al., 2006; Gallo & Nghia, 2007; Harries, Orner, Gabriel, & Mitchell, 2007; Ingham, 
Lee, Clements, & Stone, 2008; Purcell et al., 2014). In one case-controlled study of women in the United States, 
women who sought abortion after 20 weeks were much more likely to have been eight weeks pregnant or more 
at the time they discovered they were pregnant (68%), compared to women who had first-trimester abortion 
(12%)(Foster & Kimport, 2013). 
 
Ambivalence and/or difficulty with abortion decision: Some women need time to make a decision due to social 
pressures, fears, religious attitudes, and changes in relationship status. For other women, changed circumstances 
(such as abandonment by partner) cause them to seek an abortion after initially planning to carry to term (Foster 
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& Kimport, 2013; Gallo & Nghia, 2007; Harries et al., 2007). Discouraging family and friends can also delay a 
woman seeking care (Waddington, Hahn, & Reid, 2015).  
 
Financial and logistical barriers: Studies in the United States show that unemployment and lack of insurance are 
risk factors for second-trimester presentation. In addition, because second-trimester abortion is often more 
expensive, delays may be related to raising enough money to cover the cost of the procedure (Foster & Kimport, 
2013; Kiley, Yee, Niemi, Feinglass, & Simon, 2010). Poverty (Usta, Mitchell, Gebreselassie, Brookman-Amissah, & 
Kwizera, 2008), immigration status (Loeber & Wijsen, 2008) and rural residence (Bonnen et al., 2014), all of which 
make access to safe care more difficult, are all associated with late presentation. Second-trimester abortions are 
provided at a limited number of facilities and it may be difficult for women to find the time to travel. In one case-
controlled study of women presenting over 20 weeks, women needing second-trimester abortion were much 
more likely to have travelled over three hours to access care (Foster & Kimport, 2013). Second-trimester clients 
may be referred by other providers or have trouble finding a provider before finally getting care (Drey et al., 2006; 
Harries et al., 2007). Women may need to travel out of their own country to access legal second-trimester 
abortion (Loeber & Wijsen, 2008).  
 
Fetal indications: Diagnosis of fetal anomalies typically occurs after the first trimester of pregnancy, and women 
may make the decision to terminate pregnancy based on the diagnosis (Lyus, Robson, Parsons, Fisher, & Cameron, 
2013). 
 
Maternal indications: A woman may have a medical condition that worsens through the course of pregnancy or a 
new condition may arise in pregnancy that makes continuing a pregnancy dangerous to her life or health. Severe 
preeclampsia or preterm premature rupture of membranes occurring in the second trimester may require 
termination of pregnancy to save a woman’s life (American College of Obstetrics and Gynecology, 2013). 
 
Victims of violence: Victims of violence have a higher risk of late presentation (Colarossi & Dean, 2014; Perry et al., 
2015). 
 
Failed contraceptive method: Contraceptive methods may mask the early signs of pregnancy or women using 
contraception may not be aware of method failure (Foster & Kimport, 2013). 
 
Failed first-trimester abortion: Although failures are rare, women who experience an ongoing pregnancy after a 
first-trimester abortion may not discover they are still pregnant until the second trimester (Gallo & Nghia, 2007). 
 
Cultural beliefs: In rare cases there are local beliefs that having an abortion in the second trimester is safer than 
the first trimester, thus causing women to delay care (Marlow et al., 2014). 
 
Young women  
Young women are at disproportionately higher risk of needing second-trimester services.  
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Second-trimester abortion with dilatation and evacuation 
or medical abortion: Comparing methods 
 
Recommendation:  
 Dilatation and evacuation (D&E) and medical abortion with mifepristone and misoprostol or 
misoprostol only are safe and effective methods of second-trimester abortion (WHO, 2012).  
 Medical abortion has a higher rate of retained products of conception, failed abortion and 
minor adverse events.  
 Significant adverse event rates do not differ between the two methods. 
 D&E requires a trained, experienced provider and specialized equipment. 
 When both methods are available and a woman is eligible, she should be allowed to choose 
the method that is appropriate for her. 
 
Strength of recommendation: Strong 
  
Quality of evidence: Moderate 
  
Last reviewed: October 28, 2015 
 
Comparison of methods  
In retrospective cohort studies, women in the second trimester who have medical abortion have an increased 
rate of failed abortion and retained products of conception with a need for further intervention compared to 
women who have dilatation and evacuation (D&E) (Autry, Hayes, Jacobson, & Kirby, 2002; Bryant, Grimes, 
Garrett, & Stuart, 2011). However, the rate of major adverse events including infection, transfusion, 
hysterectomy and death is not increased.   
  
The largest randomized trial of second-trimester abortion methods included 122 women and showed a similar 
rate of complications for both D&E and medical abortion with mifepristone and misoprostol (Kelly, Suddes, 
Howel, Hewison, & Robson, 2010). However, women randomized to medical abortion had more bleeding and 
pain and were less satisfied than women who had D&E. A pilot randomized trial of 18 women comparing D&E 
and medical abortion with misoprostol only had a higher rate of adverse events in the women undergoing 
medical abortion (Grimes, Smith, & Witham, 2004). Both randomized trials had difficulty with recruitment due 
to women’s strong preferences for one type of procedure over another.  
  
In published studies of medical abortion compared to D&E, rates of intervention for medical abortion may be 
artificially high because failure was defined as no delivery within 24 hours (Bryant et al., 2011) and retained 
placenta was diagnosed after two hours (Grimes et al., 2004). In practice, more time may be allowed for 
successful medical abortion to occur. 
  
The importance of choice 
In settings where D&E and medical abortion are available, if a woman is a candidate for either procedure, she 
should be offered a choice. A study of women undergoing second-trimester abortions for fetal abnormalities 
demonstrated that when women chose their method, their rates of post-procedure depression did not differ 
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(Burgoine et al., 2005). Choice of methods is very individual—some women prefer the speed, predictability and 
comfort of D&E, while others prefer a more “labor-like” process with an intact fetus (Kelly et al., 2010; Kerns et 
al., 2012). Some women may want to see or hold an intact fetus while others prefer not to. In some cases, an 
intact fetus may allow for a more comprehensive fetal autopsy where it is needed. 
 
Young women   
This recommendation is the same for young women. 
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Second-trimester abortion with dilatation and evacuation  
or medical abortion: Gestational dating 
 
Recommendation:  
Accurate assessment of gestational age is important for second-trimester abortion services, especially 
when dilatation and evacuation (D&E) is used. Gestational age can be estimated by a woman’s report 
of her last menstrual period (LMP) and a physical exam. Ideally, ultrasound should be used to confirm 
the duration of pregnancy.   
 
Strength of recommendation: Strong 
  
Quality of evidence: Low 
  
Last reviewed: October 24, 2015 
 
Background 
Errors in gestational dating can increase the risks associated with second-trimester abortion. In facilities using 
dilatation and evacuation (D&E), if gestational age is underestimated, providers may not have the experience 
and equipment to complete the procedure safely. Accurate assessment of gestational age may help providers 
and women choose a safer procedure or indicate the need for referral to another facility.   
  
Dating 
There is no evidence to recommend the most appropriate way to confirm gestational age in the second 
trimester prior to abortion care (Kulier & Kapp, 2011). In the United States, 99% of providers use ultrasound in 
the second trimester, but data is lacking from other country contexts (O'Connell, Jones, Lichtenberg, & Paul, 
2008).  
  
Ideally, providers should use ultrasound to confirm the duration of the pregnancy and also use the date of the 
last menstrual period and pelvic exam to check size, consistency and position of the uterus. A single biparietal 
diameter is a simple and accurate method to confirm gestational age (Goldstein & Reeves, 2009). A femur 
length measurement can be used to confirm the biparietal diameter or used if there are technical difficulties in 
obtaining a biparietal measurement.   
  
In settings where it is not possible to confirm gestational age by ultrasound, it is extremely important that staff 
be adequately trained in pregnancy dating. After the abortion, clinicians can confirm gestational age by 
comparing actual fetal measurements (fetal foot length) to the expected gestational age (Drey, Kang, 
McFarland, & Darney, 2005). This comparison gives the clinicians feedback regarding the accuracy of their pre-
procedure dating estimates.  
  
Young women 
This recommendation is the same for young women. 
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Second-trimester abortion: Identification of fetal sex via 
ultrasound 
Key information: 
Ultrasound identification of fetal sex before 12 weeks gestation is inaccurate. Accurate identification 
between 12-16 weeks gestation depends on the technology and skill of the technician. After 16 weeks, 
fetal sex determination cannot always be made, is not perfect, and male fetuses are more likely to be 
classified as female. 
Quality of evidence: High 
Last reviewed: June 9, 2015 
In the embryo, the male and female genitals are similar in size and appearance on ultrasound until approximately 
14 weeks gestation (Elejalde, de Elejalde, & Heitman, 1985). Differences in size exist by the second and third 
trimester, and then ultrasound can be used determine fetal sex. Earlier in gestation, only indirect inferences can 
be made based on the genital tubercle which is a protuberance on the lower ventral wall of the embryo that 
eventually becomes the penis or clitoris (Colmant, Morin-Surroca, Fuchs, Fernandez, & Senat, 2013). 
The studies of ultrasound determination of fetal sex are limited by their varied methodology, especially by their 
method of determination of gestational age, which impacts the timing of fetal sex detection. However, all studies 
reported difficulties in accurate determination of sex prior to 12 weeks gestation (Efrat, Akinfenwa, & Nicolaides, 
1999; Hsiao, Wang, Hsieh, & Hsu, 2008). Sensitivity of ultrasound improved by 13 weeks gestation to 100%, but 
these studies employed state-of-the-art ultrasound technology as well as highly trained technicians (Colmant, 
Morin-Surroca, Fuchs, Fernandez, & Senat, 2013). Data from low-resource settings is more limited. A study in 
Ethiopia of women having ultrasound starting from 16 weeks showed that in 260 of 275 women (93.8%) sex was 
accurately determined (Gelaw & Bisrat, 2011). In the majority of studies, no matter the gestational age, a greater 
risk of misclassifying males as females exists.   
Young women 
This information is the same for young women. 
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Second-trimester abortion with dilatation and evacuation  
or medical abortion: Induced fetal demise 
 
Recommendation: 
Induced fetal demise prior to second-trimester medical abortion or dilatation and evacuation (D&E) 
does not increase the safety of abortion and is not recommended for medical indications. There may 
be legal or ethical indications for inducing fetal demise. 
 
Strength of recommendation: Strong 
  
Quality of evidence: Low 
  
Last reviewed: October 24, 2051 
 
Background 
Some providers use induced fetal demise prior to second-trimester medical abortion or D&E. Practices and 
techniques used vary between providers (Denny et al., 2015). In some cases, patients, providers or staff may 
prefer that fetal demise occurs before an abortion procedure (Jackson, Teplin, Drey, Thomas, & Darney, 2001). 
Before medical abortion, induced fetal demise can prevent transient fetal survival. Although the rate of 
complications in women with digoxin injection may be acceptably low in some published case series (Steward, 
Melamed, Kim, Nucatola, & Gatter, 2012), there is no current evidence that shows a medical benefit for the 
practice.     
  
Evidence related to induced fetal demise    
D&E: A randomized, controlled trial of induced fetal demise with digoxin prior to D&E which compared digoxin 
to saline injection showed no benefit to digoxin and an increased rate of vomiting (Jackson et al., 2001). A 
retrospective cohort study comparing women with digoxin injection prior to D&E with historical controls 
showed an increase in complications including more hospital admissions, extramural deliveries, and infections 
in women who had digoxin (Dean et al., 2012).   
  
Medical abortion: There are no trials to evaluate the safety and efficacy of induced fetal demise before medical 
abortion with the currently recommended second-trimester regimens.   
  
Technique  
Fetal demise can be achieved prior to a second-trimester abortion by interrupting the fetal umbilical cord or by 
injecting either potassium chloride directly into the fetal heart or digoxin into the fetus or amniotic fluid.  
  
Potassium chloride: Potassium chloride injection requires skill in ultrasound guidance techniques and has more 
potential risk due to the possibility of maternal intravascular injection, which  can cause cardiac arrest (Borgatta 
& Kapp, 2011; Coke, Baschat, Mighty, & Malinow, 2004). It is not recommended in a low-resource setting.    
  
Digoxin: In a pharmacokinetic study of eight women who had intra-amniotic injection of digoxin 1mg prior to 
second-trimester D&E, maternal serum digoxin levels were in the low therapeutic range and were not 
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associated with cardiac changes (Drey, Thomas, Benowitz, Goldschlager, & Darney, 2000). A pilot randomized 
trial of intra-amniotic or intra-fetal digoxin at doses of 1mg or 1.5mg showed an overall rate of fetal demise of 
87% with no difference in efficacy based on the dose or route of administration (Nucatola, Roth, & Gatter, 
2010). To be effective, digoxin intra-amniotic injection should be performed 1-2 days before the planned 
abortion procedure. Digoxin may be given transabdominally or transvaginally (Tocce, Sheeder, Edwards, & Teal, 
2013). 
  
Transecting the fetal cord: In one retrospective case series of 407 women having D&E between 16-23 weeks 
gestation, amniotomy was performed, and then the cord was brought to the level of the external os by electric 
vacuum aspiration and transected. Fetal asystole occurred in all cases with a mean time of 3.35 + 2.11 minutes 
(range <1-11 minutes) from the time of umbilical cord transection (Tocce, Leach, Sheeder, Nelson, & Teal, 
2013). 
 
Young women 
This recommendation is the same for young women.   
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Second-trimester abortion with dilatation and evacuation 
or medical abortion: Postabortion contraception 
 
Recommendation: 
Immediate initiation of hormonal and non-hormonal contraception following second-trimester 
dilatation and evacuation (D&E) or medical abortion is encouraged and considered safe. 
 
Strength of recommendation: Strong 
  
Quality of evidence:  
 Intrauterine device after D&E: Moderate 
 Other contraceptive methods: Low 
  
Last reviewed: October 28, 2015 
 
Contraceptive methods other than intrauterine device 
Although the immediate use of most methods of contraception has not been formally studied following second-
trimester abortion, because of the demonstrated safety of contraception after first-trimester vacuum aspiration 
and medical abortion, the World Health Organization (WHO) categorizes the immediate initiation of hormonal 
injections, implants, combined hormonal contraception (pills, patches and rings) and progestin-only pills as 
category one, or safe for use. 
 
Intrauterine device 
A Cochrane meta-analysis of 11 trials of immediate postabortion insertion of intrauterine device (IUD) following 
surgical abortion concluded that although expulsion rates may be higher with immediate placement, 
continuation is higher with no increase in complications (Grimes, Lopez, Schulz, & Stanwood, 2010). In two 
randomized controlled trials of immediate versus delayed IUD placement after second-trimester D&E, rates of 
IUD use are significantly higher with immediate insertion, and without an increase in infection or complication 
rates (Cremer et al., 2011; Hohmann et al., 2012). Expulsion rates for women who had immediate insertion in 
both studies were low (3.1% and 6.8%) and were not different from delayed insertion. Notably, in both of these 
studies, about half of women randomized to delayed insertion did not come back to have the IUD inserted. 
Requiring a follow-up visit for IUD insertion is a significant barrier to obtaining the IUD (Stanek, Bednarek, 
Nichols, Jensen, & Edelman, 2009).  
 
No studies exist of IUD placement immediately following second-trimester medical abortion and the WHO 
Medical Eligibility Criteria recommendations do not differ based on the type of abortion performed, whether 
medical or surgical. Although not directly translatable, the evidence from post-partum IUD insertion is 
reassuring (Grimes, Shulz, Van Vliet, & Stanwood, 2007). Because of the possible increased risk of expulsion, the 
WHO classifies IUD insertion after an uncomplicated second-trimester abortion as category two, which means 
the advantages of using the method generally outweigh the risks (WHO, 2009). 
 
Quality of evidence  
There is limited clinical data to support the recommendation of starting methods other than the IUD 
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immediately after second-trimester D&E. This recommendation is based on expert opinion (WHO, 2015). A 
woman's immediate need for reliable contraception after abortion, coupled with the risk that delayed 
contraceptive provision reduces uptake, strongly supports the recommendation to start these methods 
immediately. 
  
Young women 
The IUD for women under the age of 20 is classified by WHO as category two, in which the benefits generally 
outweigh the risks. While risk is slightly increased due to higher rates of sexually transmitted infections and 
expulsion in this patient population, IUDs are still a safe, effective and recommended method for women under 
the age of 20. Depot medroxyprogesterone acetate injection is also classified by WHO as a category two for 
women less than 18 years of age, due to theoretical concerns about bone mineral density. Sterilization may be 
performed, but a young woman will need special precautions due to the increased risk of regret (WHO, 2015). 
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Second-trimester abortion with dilatation and evacuation  
or medical abortion: Follow-up 
 
Recommendation:  
Routine follow-up care is not necessary unless desired or requested by the woman or necessary for 
her chosen contraceptive method. She should receive adequate information regarding her 
postabortion care and warning signs to watch for prior to being sent home. 
 
Strength of recommendation: Weak 
  
Quality of evidence: Very low 
  
Last reviewed: October 24, 2015 
 
Follow-up 
There is no scientific data to demonstrate that routine follow-up is beneficial after second-trimester abortion 
performed by a trained health-care provider. In addition, there is no evidence to suggest that a pelvic 
examination is beneficial in an asymptomatic woman if she does return for a routine follow-up visit.  
  
Young women 
This recommendation is the same for young women.   
  
Quality of evidence 
Very low. The recommendation is based on expert opinion (World Health Organization, 2012). 
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Second-trimester abortion with dilation and evacuation or 
medical abortion: Safe disposal of products of conception 
    
Recommendation: 
Follow standards and guidelines from your setting for disposal of products of conception. For low-
resource settings, burial in a properly built and maintained pit (placenta pit) is a recommended disposal 
method (WHO, 2014). 
 
Strength of recommendation: Strong 
  
Quality of evidence: High 
  
Last reviewed:  October 28, 2015 
 
Background 
Products of conception are pathologic waste, which is a category of health-care waste that includes human tissues, 
blood and bodily fluids. Pathologic waste is considered infectious waste because it is capable of spreading blood-
borne diseases. Proper management of infectious waste is important to reduce health risks and environmental 
pollution.  
  
Recommendations for first- and second-trimester products of conception are the same. Products of conception 
should be handled in accordance with prevailing religious, cultural and aesthetic norms. Unless local funeral 
procedures are being observed, disposal should be in accordance with guidelines for infectious waste.   
 
Pathological waste handling, sorting, storage and transport 
Handling: Personnel who handle pathologic waste should wear appropriate protective clothing (heavy-duty gloves, 
industrial apron, overalls/coveralls, leg protectors and/or industrial boots, face mask). Staff should handle 
pathological waste as little as possible before disposal.  
  
Sorting: Pathologic waste should be separated from other health-care waste, placed in a leak-proof plastic bag or 
sealed container, and clearly marked with a biohazard symbol.  
  
Interim storage: Interim storage should ideally be short-term. Usually waste should be stored for only a few hours 
before disposal. If the pathologic waste must be stored, the storage area should be secure, contained, and marked 
by a biohazard sign. The storage area should be sealed or tiled to allow easy disinfection. The time from generation 
of the waste to treatment should not exceed the following:   
 
Temperate climate Warm climate 
72 hours in winter 48 hours during the cool season 
48 hours in summer 24 hours during the hot season 
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Transport: Some health facilities will dispose of pathologic waste off-site. Since the transport staff will be handling 
the waste, they must be educated about the infectious nature of the waste as well as the sensitivity surrounding 
the disposal of products of conception. 
 
On-site pathologic waste disposal  
Burial: Burial of pathologic waste in a properly built and maintained pit (“placenta pit”) to allow for natural 
biodegradation is suitable for low-resource areas. The type of pit and dimensions should be built according to the 
amount of infectious waste the facility produces. Guidelines for pit construction can be found in the 
EngenderHealth, World Health Organization (WHO), Médecins Sans Frontières and Jhpiego manuals in the 
reference section. Some basic rules to follow include: 
 Restrict access to authorized personnel only, and fence in the area to keep out animals, scavengers and 
children. 
 Line the pit with a material of low permeability (clay, dung, river silt); a cement bottom should be used if 
available. 
 The bottom of the pit should be at least 1.5 to two meters above the groundwater level and at least 50 
meters from crops or water sources; the pit should be located away from areas that flood.  
 Only infectious waste should be buried. 
 Each waste layer should be covered by a 10cm layer of soil (ash or charcoal can also be used to reduce odor 
and speed up decomposition). 
 The pit should be closed when the waste is 50cm below the ground surface. 
 
Incineration: The benefit of incineration is a reduction in waste volume and weight and the elimination of 
microorganisms and recognizable material. Incinerators can range from large, sophisticated, permanent, high-
temperature industrial models to very basic small ones (such as drum or brick units) that operate at much lower 
temperatures. Burning in an industrial incinerator is preferred, but if one is not available, a drum or brick 
incinerator can be used. Incinerators, particularly simple units, may release toxic chemicals into the air and do not 
run efficiently when burning pathologic waste with high moisture content.        
  
If small incinerators are the only option, best practices include: 
 Effective waste reduction and segregation, ensuring only the smallest amount of combustible waste is 
incinerated 
 Using a design engineered to reach sufficient temperatures to allow complete combustion 
 Placing incinerators away and downwind from health-care buildings and residential areas or where crops 
are grown 
 Using a clearly described method of operation 
 Periodic maintenance 
 Not incinerating certain waste, which includes pressurized gas containers (aerosol cans), reactive chemical 
waste, silversalts and photographic/radiographic wastes, polyvinyl chloride (PVC) plastics, or waste with 
high mercury or cadmium content 
 
Important: Construction guidelines for incinerators can be found in the EngenderHealth, WHO, Medecins Sans 
Frontieres and Jhpiego manuals in the reference section.  
 
Pouring into a safe sewage system: Liquid infectious waste may be poured directly into a sink or drain connected to 
an adequately treated sewer or pit latrine. Rinse the sink, drain or toilet thoroughly and clean with disinfectant 
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cleaning solution daily or more frequently if heavily used or soiled (EngenderHealth, 2011; Tietjen, Bossemeyer, & 
MacIntosh, 2003).  
  
Open-air burning: Open-air burning is not recommended. If it is the only option available, it should be done in a 
confined area (in a dugout pit and covered with soil when finished). 
 
Open dumping: Open dumping is never an acceptable option due to the infectious nature of pathologic waste. 
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Second-trimester dilatation and evacuation: Cervical 
preparation 
 
Recommendation:  
 Routine preoperative cervical preparation is recommended before dilatation and evacuation 
(D&E) (WHO, 2012). 
 Osmotic dilators, misoprostol and mifepristone are all choices for cervical preparation. The 
choice depends on availability, expense, gestational age and timing of the procedure.    
 
Strength of recommendation: Strong 
  
Quality of evidence: High 
  
Last reviewed: October 20, 2015 
 
Background 
Cervical preparation prior to second-trimester dilatation and evacuation reduces the risk of complications (Fox 
& Krajewski, 2013; Peterson, Berry, Grace, & Gulbranson, 1983). Some methods, including misoprostol and 
synthetic osmotic dilators, may be used for same-day cervical preparation in the early second trimester. There 
is limited data to suggest the best method because the trials that exist have heterogeneous comparisons, small 
enrollment numbers and include few women with pregnancies over 20 weeks. Although trials may show 
differences in cervical dilation, they are not large enough to show differences in more serious outcomes like 
cervical or uterine injuries or inability to complete the procedure (Newmann et al., 2010). Moreover, method 
choice is often limited by availability, especially in low-resource settings.  
 
Possible cervical preparation methods include: 
 
Method Dosing Note 
Osmotic dilators  
(laminaria or synthetic osmotic 
dilators) 
6-24 hours prior to procedure Synthetic osmotic dilators may be 
used the day of the D&E 
Misoprostol 400mcg buccally or vaginally 3 
hours prior to procedure 
Limited data to support use as a 
single agent over 18-20 weeks  
 
May be combined with osmotic 
dilators or mifepristone  
 
May be repeated as needed 
Mifepristone 200mg orally 24-48 hours prior to 
procedure 
No data to support use as a single 
agent over 16 weeks  
 
May be combined with 
misoprostol 
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Osmotic dilators 
Numerous cohort studies have demonstrated that osmotic dilators are safe and effective and their use does not 
increase infectious morbidity (Bryman, Granberg, & Norström, 1988; Fox & Krajewski, 2013; Jonasson, Larsson, 
Bygdeman, & Forsum, 1989; Peterson et al., 1983). A Cochrane meta-analysis of cervical preparation before 
D&E showed that osmotic dilators provide better cervical dilation when compared to prostaglandins 
throughout the second trimester and decreased procedure time in the early second trimester. There is not 
sufficient evidence to recommend a specific dilator type (laminaria or synthetic dilators) or regimen (Newmann, 
Dalve-Endres, & Drey, 2008). Decisions about the number and timing of dilators to place should be 
individualized and take into consideration the dilator's type and size, the woman’s gestational age, parity and 
cervical compliance, and the provider’s experience (Fox & Krajewski, 2013; Newmann et al., 2008).  
 
Misoprostol 
Misoprostol has been studied as an alternative or supplement to osmotic dilators and has been used as a single 
agent for cervical preparation before 16-18 weeks gestation. Multiple small randomized trials have compared 
misoprostol to dilators (Goldberg et al., 2005; Bartz, Maurer, Allen, Fortin, Kuang, & Goldberg, 2013; Sagiv et 
al., 2015). Studies have looked at different gestational ages, different misoprostol doses and routes, and 
different dilator types, however all studies found that all women were able to have their procedures completed 
on the same day as cervical preparation. In some cases dilators provided more procedural dilation, however 
women often preferred misoprostol.  
 
Misoprostol  is inexpensive, safe (Nucatola, Roth, Saulsberry, & Gatter, 2008), and more readily available than 
osmotic dilators in some low-resource settings, and may be used for cervical preparation prior to D&E up to 18 
weeks gestation (Baird, Castleman, Hyman, Gringle, & Blumenthal, 2007). Misoprostol may be given to women 
with a prior cesarean delivery, as uterine rupture is rare (Fox & Hayes, 2007).  
 
Misoprostol plus laminaria 
Two randomized controlled trials have shown that misoprostol added to laminaria improves cervical dilation 
and operating time over 19-21 weeks (Edelman, Buckmaster, Goetsch, Nichols, & Jensen, 2006; Drey et al., 
2013). This effect was not seen at lower gestational ages and side effects were greater with women using 
misoprostol.    
  
Mifepristone 
In a randomized trial of 50 women between 14-16 weeks gestation, women who had cervical preparation with 
osmotic dilators had a slightly shorter procedure time and greater dilation compared to mifepristone, but 
women had less pain with mifepristone and strongly preferred mifepristone to osmotic dilators (Borgatta et al., 
2012).  
 
In one randomized clinical trial of 900 women between 12-20 weeks gestation given mifepristone with 
misoprostol, the combined regimen improved dilation compared to misoprostol alone but had an increased 
rate of preprocedure fetal expulsions (Carbonell et al., 2007). A single-center retrospective cohort study of 512 
women from 14-19 weeks showed mifepristone and misoprostol prior to D&E to be as effective as misoprostol 
alone or misoprostol and laminaria (Searle, Tait, Langdana, & Maharaj, 2014).   
 
Finally, one small randomized, non-inferiority trial of 50 women between 19 and 23 and 6/7 weeks gestation 
compared mifepristone used with one set of osmotic dilators one day prior to D&E procedure compared to two 
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sets of dilators inserted serially over two days without mifepristone. All women received misoprostol on the 
day of their procedure (Shaw et al., 2015). There were no differences in procedure time or cervical dilation. 
  
Young women 
This recommendation is the same for young women. 
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Second-trimester dilatation and evacuation: Pain 
management 
 
Recommendation:  
 Women undergoing second-trimester dilatation and evacuation (D&E) should receive pain 
medications and non-pharmacologic approaches to treat pain (WHO, 2012).  
 A combination regimen of local anesthesia (paracervical block), non-steroidal anti-
inflammatory drugs and narcotic analgesics with or without anxiolytics is recommended. If the 
personnel, monitoring and equipment are available to safely provide deeper levels of sedation, 
these services may be offered. The increased risks of deep sedation or general anesthesia must 
be weighed against the benefits to the woman.  
 
Strength of recommendation: Strong 
  
Quality of evidence: Low 
  
Last reviewed: October 24, 2015 
 
Pain during second-trimester dilatation and evacuation 
There is a lack of published evidence regarding the level of pain associated with dilatation and evacuation 
(D&E). Most experts agree that D&E is more painful than first-trimester vacuum aspiration; D&E requires more 
dilation, longer procedure times and deeper uterine manipulation. 
  
Regimens for pain control 
Specific studies in second-trimester D&E are lacking. The optimal regimen for pain management has not been 
established. Most international consensus statements focus on the minimum amount of anesthesia at which a 
D&E can be performed to ensure access at lower-level facilities rather than optimizing pain control (Royal 
College of Obstetrician and Gynaecologists, 2011; World Health Organization [WHO], 2012). Ipas recommends a 
combination of local anesthesia (paracervical block) with nonsteroidal anti-inflammatory drugs (NSAIDs) and 
narcotic analgesics with or without anxiolytics. Medications may be given orally or parenterally (Baird, 
Castleman, Hyman, Gringle, & Blumenthal, 2007).   
 
Some women may need deeper sedation based on the clinical situation. Intravenous sedation may be offered in 
facilities where there is a trained provider with adequate equipment for patient monitoring. General anesthesia 
increases the risks associated with abortion and is not recommended for routine procedures (Atrash, Cheek, & 
Hogue, 1988; WHO, 2012). If general anesthesia is used, the addition of a paracervical block does not appear to 
help with postoperative pain control (Lazenby, Fogelson, & Aeby, 2009). Medication choice and sedation level 
depend on the woman’s preference as well as the level of provider training, supplies and monitoring equipment 
in the facility.  
  
Young women 
This recommendation is the same for young women. 
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Second-trimester dilatation and evacuation: Prophylactic 
antibiotics  
 
Recommendation:  
Administer prophylactic antibiotics for all women prior to dilatation and evacuation (D&E). Where 
antibiotics are unavailable, D&E may still be offered. Some providers start antibiotics at the time of 
osmotic dilator placement, but there are no studies comparing different start times and the risk of 
infection. 
 
Strength of recommendation: Strong 
  
Quality of evidence: Low 
  
Last reviewed: October 23, 2015 
 
Background  
There is evidence to support the use of prophylactic antibiotics before first-trimester vacuum aspiration. 
However, evidence in the second trimester is more limited. Because of the demonstrated benefit of first-
trimester antibiotics, the World Health Organization (2012), Society of Family Planning (Achilles & Reeves, 
2011), American Congress of Obstetricians and Gynecologists (2009) and Royal College of Obstetricians and 
Gynaecologists (2011) recommend prophylactic antibiotics for all women having D&E. Giving prophylactic 
antibiotics is more effective (Levallois & Rioux, 1988) and cheaper (Penney et al., 1998) than screening all 
women and treating only those with evidence of infection. Because the rate of infection after D&E is very low, 
the inability to provide antibiotics should not limit access to abortion (Peterson, Berry, Grace, & Gulbranson, 
1983; WHO, 2012).  
  
Regimen  
Many antibiotic regimens for abortion prophylaxis have been studied, but the ideal antibiotic, dose and timing 
has not yet been established (Achilles & Reeves, 2011). Tetracyclines (doxycycline) and nitroimidazoles 
(metronidazole and tinidizole) are commonly used because of their clinical efficacy, oral availability, low cost 
and low risk of allergic reactions (Achilles & Reeves, 2011; O'Connell, Jones, Lichtenberg, & Paul, 2008). 
Although studies of abortion are limited (Caruso et al., 2008) evidence from the obstetrical (Costantine et al., 
2008), gynecologic (Mittendorf et al., 1993) and general surgery (Classen et al., 1992) literature supports the 
practice of giving antibiotics before the procedure to decrease the risk of infection. Antibiotic regimens do not 
need to be extended beyond the immediate postabortion period (Achilles & Reeves, 2011; Levallois & Rioux, 
1988; Caruso et al., 2008; Lichtenberg & Shott, 2003).  
 
The following table lists some common regimens used in clinical practice or recommended by professional 
organizations. These regimens are based on clinical evidence and expert opinion. Providers should choose a 
regimen based on the expense and availability of the antibiotics as well as practices around testing and treating 
women for sexually transmitted infections.  
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Common regimens Recommender 
Doxycycline 100mg orally 1 hour before the 
procedure and 200mg after the procedure 
or 
Metronidazole 500mg orally twice daily for 5 days 
American Congress of Obstetricians and 
Gynecologists (2009) 
Doxycycline 200mg orally before the procedure 
or 
Azithromycin 500mg orally before the procedure 
or 
Metronidazole 500mg orally before the procedure 
Planned Parenthood Federation of America (Manual 
of Medical Standards and Guidelines, 2014) 
 
Antibiotics with cervical preparation 
Although not well studied, cervical preparation with osmotic dilators does not appear to increase the risk of 
infection (Fox & Hayes, 2007; Jonasson, Larsson, Bygdeman, & Forsum, 1989). Some providers start antibiotics 
at the time of osmotic dilator placement, but there are no studies comparing different start times and the risk 
of infection (O'Connell et al., 2008). 
 
Therapeutic antibiotics 
If possible, women at high risk should be screened and treated for sexually transmitted infections in addition to 
receiving prophylactic antibiotics. Women who have signs and symptoms of active infection should be provided 
with abortion services without delay and treated appropriately once the procedure is completed. 
  
Young women 
This recommendation is the same for young women. 
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Second-trimester medical abortion: Previous uterine scar 
 
Recommendation:  
Less than 22-24 weeks gestation with one uterine scar 
No changes to recommended regimens necessary.  
 
More than 22-24 weeks gestation with one uterine scar or throughout second trimester with more 
than one uterine scar 
Consider removing the misoprostol loading dose and decreasing the misoprostol dose with or without 
increasing the misoprostol dosing interval.  There is insufficient evidence to suggest that these 
interventions will decrease the risk of uterine rupture in these women.   
 
Strength of recommendation: Weak 
 
Quality of evidence: Very Low 
  
Last reviewed: October 21, 2015 
 
Risk of uterine rupture with medical abortion 
Uterine rupture has been reported during second-trimester medical abortion in women both with and without 
a uterine scar. The risk of uterine rupture for any woman undergoing a second-trimester medical abortion is 
very rare, occurring in less than 1 in 1,000 women (Goyal, 2009). In a meta-analysis of 16 studies of 3,556 
women undergoing second-trimester medical abortion with combined or misoprostol-only regimens, there 
were three women who suffered uterine rupture resulting in a rate of 0.28% with a previous cesarean section 
and 0.04% without a previous cesarean section (Goyal, 2009).   
  
One single-center retrospective review of 279 women undergoing second-trimester abortion with misoprostol 
every four hours included 26 women with more than one scar. These women received misoprostol 200mcg 
every four hours; three had a uterine rupture (Küçükgöz Güleç et al., 2013).  
 
Regimen for women with a uterine scar 
Due to the rarity of uterine rupture in women with a previous scar, no clear guidance can be obtained from the 
published literature (Borgatta & Kapp, 2011; Daponte, Nzewenga, Dimopoulos, & Guidozzi, 2006; Daskalakis et 
al., 2004; Dickinson, 2005).   
  
Expert opinion supports: 
1. No change in medical abortion regimen for women whose gestation is less than 22-24 weeks.  
2. After 22-24 weeks gestation with a single uterine scar or throughout the second trimester with more 
than one uterine scar: 
 Do not use a misoprostol loading dose. 
 Consider decreasing the dose of misoprostol with or without increasing the dosing interval (Ho 
et al., 2007; Küçükgöz Güleç et al., 2013). 
 There is insufficient evidence to suggest that changing the dosing regimen will decrease the risk 
of uterine rupture.  
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Young women 
This recommendation is the same for young women. 
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Second-trimester medical abortion: Pain management  
 
Recommendation:  
 All women undergoing medical abortion in the second trimester should be offered pain 
management (WHO, 2012). 
 Prophylactic non-steroidal anti-inflammatory drugs reduce the need for narcotic analgesics 
during second-trimester medical abortion. 
 All women should be given nonsteroidal anti-inflammatory drug (NSAIDs) when they begin 
misoprostol. Narcotic analgesics, anxiolytics, and non-pharmacologic measures may be used as 
needed. If the personnel, monitoring and equipment are available, regional anesthesia or 
patient-controlled anesthesia may be offered. 
 
Strength of recommendation: Strong  
  
Quality of evidence: Low 
  
Last reviewed: October 24, 2015 
 
Pain during second-trimester medical abortion 
In multiple cohort studies of second-trimester medical abortion, the majority of women require pain 
medication (Ashok, Templeton, Wagaarachchi, & Flett, 2004; Gemzell-Danielsson & Östlund, 2000; Goh & 
Thong, 2006; Hamoda, Ashok, Flett, & Templeton, 2004; Rose, Shand, & Simmons, 2006). Advanced gestational 
age, number of misoprostol doses and induction-to-abortion interval are associated with increased pain during 
medical abortion (Hamoda et al., 2004). Pain rarely starts after taking mifepristone but becomes more 
pronounced after misoprostol and typically peaks with expulsion.     
  
Regimens for pain control 
All women undergoing medical abortion in the second trimester should be offered pain management, but there 
is little evidence regarding the optimal regimen. One randomized trial of 74 women undergoing second-
trimester medical abortion with mifepristone and misoprostol found that prophylactic treatment with a 
nonsteroidal anti-inflammatory drug (NSAID) (in this study, diclofenac 100mg orally) at the time of misoprostol 
administration reduced the need for intravenous opiates when compared to treatment with paracetamol and 
codeine (Fiala, Swahn, Stephansson, & Gemzell-Danielsson, 2005). In this study, treatment with NSAIDs did not 
affect abortion outcome.    
  
In the largest cohort study of 1,002 women having second-trimester mifepristone and misoprostol medical 
abortion, a combination of oral and parenteral narcotic analgesics and NSAIDs was provided at 4-6 hour 
intervals as required (Ashok et al., 2004). Although it is not evidence based, a combination regimen involving 
prophylactic NSAIDs given at the time of misoprostol, plus oral and/or parenteral narcotic analgesics, is an 
effective way of delivering pain management according to a woman’s particular needs (Baird, Castleman, 
Hyman, Gringle, & Blumenthal, 2007). If the personnel, monitoring and equipment are available, regional 
(epidural) or patient-controlled anesthesia may be offered.   
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Young women 
This recommendation is the same for young women. 
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Second-trimester medical abortion with mifepristone and 
misoprostol: Safety and efficacy 
 
Key information: 
A combined regimen with mifepristone and misoprostol is recommended over a misoprostol-only 
regimen for second-trimester medical abortion (WHO, 2012). The combined regimen is safe and 
effective, with expulsion rates of over 99%, induction-to-abortion time of around six hours and major 
complication rates of less than 1%. 
 
Quality of evidence: High 
  
Last reviewed: October28, 2015 
 
Expulsion rates 
In the largest cohort study of 1,002 women having second-trimester medical abortion using the recommended 
mifepristone and misoprostol regimen, the complete expulsion rate was 98.3% at 24 hours and 99.2% at 36 
hours (Ashok, Templeton, Wagaarachchi, & Flett, 2004). 
  
Induction-to-abortion interval 
In the cohort study mentioned above, the median time to fetal expulsion was 6.25 hours, with a range of 0-67.5 
hours. The induction-to-abortion interval was longer in nulliparous women, older women and women at a later 
gestational age (Ashok et al., 2004). The addition of mifepristone to the medical abortion regimen consistently 
reduces the induction-to-abortion interval (Dabash et al., 2015; Kapp, Borgatta, Stubblefield, Vragovic, & 
Moreno, 2007; Ngoc et al., 2011).   
 
Complication rates 
The rate of major complications from mifepristone and misoprostol medical abortion in the second trimester is 
low, although minor complications—such as needing a procedure for bleeding or retained products of 
conception—are more frequent than for dilatation and evacuation (Autry, Hayes, Jacobson, & Kirby, 2002). In 
the cohort study of 1,002 women, 81 women (8.1%) needed surgery for uterine evacuation, the majority for 
retained placenta. Only two out of the 1,002 women needed a surgical evacuation to terminate the pregnancy 
(Ashok et al., 2004). In this study, serious complications such as hemorrhage, blood transfusion or 
unanticipated surgery occurred in eight women (<1%).  
 
In a meta-analysis of studies of medical abortion, the overall rate of uterine rupture is 0.08%, with a rate of 
0.28% in women with a previous cesarean section (Goyal, 2009). A Finnish register-based study of women who 
had a medical abortion in either the first (3,427 women) or second (416 women) trimester compared incidence 
of several factors—preterm birth, low birth weight, small-for-gestational-age infants and placental 
complications—in subsequent pregnancies (Mannisto et al., 2014). No differences were observed between the 
two groups, suggesting second-trimester medical abortion does not increase risk of these outcomes in 
subsequent pregnancies compared to first-trimester medical abortion. 
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Second-trimester medical abortion with mifepristone and 
misoprostol: Recommended regimen  
 
Recommendation:  
13-24 weeks gestation: Mifepristone 200mg by mouth, followed 24-48 hours later by misoprostol 
800mcg vaginally for one dose, then 400mcg vaginally or sublingually every three hours for four more 
doses (WHO, 2012). 
 
Strength of recommendation: Strong 
  
Quality of evidence:  
Up to 20 weeks gestation: Moderate  
20-24 weeks gestation: Low  
  
Last reviewed: October 28, 2015 
 
Background 
Mifepristone combined with misoprostol is the preferred regimen for medical abortion in the second trimester, 
as it combines high efficacy, a short induction-to-abortion interval and an excellent safety profile (Dabash et al., 
2015; Wildschut et al., 2011).  
  
Mifepristone dose and timing 
Mifepristone 200mg given orally is as effective as a 600mg oral dose (Webster, Penney, & Templeton, 1996). 
When mifepristone is given 12-24 hours instead of 36-48 hours before misoprostol, the induction-to-abortion 
interval is slightly longer but the abortion rate at 24 hours is similar (Shaw, Topp, Shaw, & Blumenthal, 2013). 
Simultaneous dosing of mifepristone and misoprostol can be a useful strategy if medical or social issues require 
an even shorter time interval between the two medications (Chai et al., 2009) because the combined regimen 
at any timing is more effective than misoprostol alone. 
 
Misoprostol loading dose 
Published clinical trials have used a higher loading dose of vaginal misoprostol 600mcg (Chai et al., 2009; el-
Refaey & Templeton, 1995) or 800mcg (Hamoda, Ashok, Flett, & Templeton, 2005). The largest case series of 
1,002 women undergoing second-trimester abortion with mifepristone and misoprostol used a loading dose of 
misoprostol 800mcg vaginally with a resulting median induction-to-abortion interval of 6.25 hours and 24-hour 
efficacy of 97.1% (Ashok, Templeton, Wagaarachchi, & Flett, 2004). When compared to the 800mcg vaginal 
loading dose, a 600mcg sublingual loading dose has similar efficacy but higher pain medication requirements 
(Hamoda et al., 2005). A single, small randomized controlled trial assigned 77 women to receive a loading dose 
of misoprostol vaginally (600mcg, followed by 400mcg every six hours) and 80 to a no-loading dose regimen 
(400mcg every six hours) (Pongsatha & Tongsong, 2014). Median induction-to-abortion intervals and rates of 
complete abortion at 24 and 48 hours did not differ between groups; the loading dose group suffered 
significantly more misoprostol-related side effects. 
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Misoprostol dosing 
Route: Vaginal dosing has superior efficacy when compared to oral dosing (Wildschut et al., 2011). Sublingual 
dosing has similar efficacy to vaginal, but it is associated with higher pain medication requirements (Hamoda et 
al., 2005). Oral dosing is inferior to vaginal and sublingual dosing (Ho, Ngai, Liu, Wong, & Lee, 1997; Tang, Chan, 
Kan, & Ho, 2005). More research is needed to determine the most effective dose and timing for buccal 
misoprostol (Garg et al., 2015; Ellis, Kapp, Vragpvoc, & Borgata, 2010).   
  
Dose: Misoprostol 400mcg vaginally has higher expulsion rates, shorter induction-to-abortion intervals and 
similar side effects compared to 200mcg vaginally (Brouns, van Wely, Burger, & van Wijngaarden, 2010). The 
400mcg dose is equally effective when given sublingually (Hamoda et al., 2005). 
  
Timing: In studies of misoprostol only, induction-to-abortion intervals were shorter and efficacy at 24 hours was 
higher when misoprostol was given every three hours compared to every six hours with similar rates of adverse 
events (Wong, Ngai, Yeo, Tang, & Ho, 2000). 
 
Quality of evidence: The recommendation is based on multiple randomized clinical trials and a Cochrane meta-
analysis comparing different mifepristone and misoprostol doses, dosing intervals and routes of administration 
in the second trimester (Wildschut et al., 2011). Most randomized controlled trials of medical abortion in the 
second trimester do not include women over 20 weeks gestation. 
  
Young women 
This recommendation is the same for young women. 
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Second-trimester medical abortion with misoprostol only: 
Safety and efficacy 
 
Key information: 
A combined regimen with mifepristone and misoprostol is recommended for second-trimester 
medical abortion (WHO, 2012). Where mifepristone is not available, misoprostol only is safe and 
effective with expulsion rates of over 90% at 48 hours, average induction-to-abortion time of around 
12 hours and major complication rates of less than 1%.  
  
Quality of evidence: Moderate 
  
Last reviewed: October 31, 2015 
 
Expulsion rates 
In the largest international randomized controlled trial of 681 women having second-trimester medical abortion 
using the recommended misoprostol-only regimen, the complete expulsion rate was 84.8% at 24 hours and 
94.3% at 48 hours (Von Hertzen et al., 2009). Other randomized trials using vaginal or sublingual misoprostol 
every three hours show similar expulsion rates of 90-95% at 48 hours (Bhattacharjee, Saha, Ghoshroy, 
Bhowmik, & Barui, 2008; Tang, Lau, Chan, & Ho, 2004). In nulliparous women, vaginal misoprostol has higher 
expulsion rates than sublingual misoprostol (Von Hertzen et al., 2009). 
  
Induction-to-abortion interval 
In the trial cited above, the median time to fetal expulsion was 12 hours with a range of 4.1-61.8 hours, with 
parous women having faster induction-to-abortion times than nulliparous women (Von Hertzen et al., 2009). 
Increasing the dosing interval of misoprostol increases the induction-to-abortion time (Wong, Ngai, Yeo, Tang, 
& Ho, 2000).   
  
Complication rates 
The rate of major complications from misoprostol-only abortion in the second trimester is low. In the trial cited 
above, 12 adverse events (0.02%) were reported, with none of them being serious (Von Hertzen et al., 2009); 
10 women required blood transfusions.     
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Second-trimester medical abortion with misoprostol only: 
Recommended regimen 
 
Recommendation:  
13-24 weeks gestation: Misoprostol 400mcg vaginally or sublingually every three hours for up to five 
doses. Vaginal dosing is more effective than sublingual dosing for nulliparous women (WHO, 2012).    
   
Strength of recommendation: Strong 
  
Quality of evidence:  
Up to 20 weeks gestation: Moderate  
20-24 weeks gestation: Low   
  
Last reviewed: October 31, 2015 
 
Background 
In the second trimester, a combination regimen with mifepristone and misoprostol has shorter induction-to-
abortion intervals and higher success rates than misoprostol only (Wildschut et al., 2011). If mifepristone is not 
available, a misoprostol-only regimen with dosing every three hours is an acceptable alternative (Wildschut et 
al., 2011; World Health Organization [WHO], 2012).   
  
Vaginal route 
In randomized controlled clinical trials, misoprostol 400mcg vaginally every three hours is associated with a 
median induction-to-abortion interval of 10-15 hours and a 48-hour successful abortion rate of 90-95% 
(Bhattacharjee, Saha, Ghoshroy, Bhowmik, & Barui, 2008; Tang, Lau, Chan, & Ho, 2004; von Hertzen et al., 
2009). Increasing the dosing interval decreases the efficacy of medical abortion (Wong, Ngai, Yeo, Tang, & Ho, 
2000). 
   
Sublingual route 
In a meta-analysis of 1,178 women from three randomized controlled trials, misoprostol 400mcg sublingually is 
similar (Bhattacharjee et al., 2008) or slightly inferior to vaginal dosing when given every three hours (Tang et 
al., 2004; von Hertzen et al., 2009; Wildschut et al., 2011). In the trials that showed reduced efficacy, the 
difference was driven by an inferior response to sublingual misoprostol in nulliparous women only. Of note, all 
of these studies found women prefer the sublingual route to the vaginal route.   
   
Other routes 
Buccal route: One trial randomized 130 women to misoprostol 400mcg every three hours either vaginally or 
buccally; women in the vaginal group had a shorter induction-to-abortion interval and completion rate at both 
24 and 48 hours (Al & Yapca, 2015). A smaller trial of 64 women showed buccal misoprostol was as effective as 
vaginal misoprostol, however all of the women in this trial received a loading dose of misoprostol 400mcg 
vaginally and were randomized to 200mcg buccally or vaginally every six hours (Ellis, Kapp, Vragpvoc, & 
Borgatta, 2010). More studies are needed before recommending buccal misoprostol for this purpose.  
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Oral route: In multiple randomized clinical trials, oral dosing has been shown to be less effective with longer 
induction-to-abortion intervals than vaginal or sublingual dosing (Nautiyal et al., 2015; Akoury et al., 2004; 
Bebbington et al., 2002; Behrashi & Mahdian, 2008).  
  
Quality of evidence: The recommendation is based on multiple randomized clinical trials and a Cochrane meta-
analysis comparing different misoprostol doses, dosing intervals and routes of administration in the second 
trimester (Wildschut et al., 2011). Most randomized controlled trials of medical abortion in the second 
trimester do not include women over 20 week’s gestation. 
  
Young women   
This recommendation is the same for young women.   
 
References  
Akoury, H. A., Hannah, M. E., Chitayat, D., Thomas, M., Winsor, E., Ferris, L. E., Windrim, R. (2004). Randomized 
controlled trial of misoprostol for second-trimester pregnancy termination associated with fetal malformation. 
American Journal of Obstetrics & Gynecology, 190(3), 755-762.  
 
Al, R. A., & Yapca, O. E. (2015). Vaginal misoprostol compared with buccal misoprostol for termination of 
second-trimester pregnancy: a randomized controlled trial. Obstetrics & Gynecology, 126(3), 593-8. 
  
Bebbington, M. W., Kent, N., Lim, K., Gagnon, A., Delisle, M. F., Tessier, F., & Wilson, R. D. (2002). A randomized 
controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. 
American Journal of Obstetrics & Gynecology, 187(4), 853-857.  
  
Behrashi, M., & Mahdian, M. (2008). Vaginal versus oral misoprostol for second-trimester pregnancy 
termination: a randomized trial. Pakistan Journal of Biological Sciences, 11(21), 2505-2508.  
 
Bhattacharjee, N., Saha, S. P., Ghoshroy, S. C., Bhowmik, S., & Barui, G. (2008). A randomised comparative study 
on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 
weeks. Australian and New Zealand Journal of Obstetrics and Gynaecology, 48(2), 165-171.  
 
Ellis, S. C., Kapp, N., Vragovic, O., & Borgatta, L. (2010). Randomized trial of buccal versus vaginal misoprostol 
for induction of second trimester abortion. Contraception, 81(5), 441-445.  
 
Nautiyal, D., Mukherjee, K., Perhar, I., & Banerjee, N. (2015). Comparative study of misoprostol in first and 
second trimester abortions by oral, sublingual and vaginal routes. Journal of Obstetrics and Gynecology of India, 
65(4), 246-50. 
 
Tang, O. S., Lau, W. N., Chan, C. C., & Ho, P. C. (2004). A prospective randomised comparison of sublingual and 
vaginal misoprostol in second trimester termination of pregnancy. BJOG: An International Journal of Obstetrics 
& Gynecology, 111(9), 1001-1005.  
 
von Hertzen, H., Piaggio, G., Wojdyla, D., Nguyen, T. M., Marions, L., Okoev, G.,Peregoudov, A. (2009). 
Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled 
equivalence trial. Human Reproduction, 24(1), 106-112.  
 
Clinical Updates in Reproductive Health                        www.ipas.org/clinicalupdates 
 
                                                                          119 
 
Wildschut, H., Both, M. I., Medema, S., Thomee, E., Wildhagen, M. F., & Kapp, N. (2011). Medical methods for 
mid-trimester termination of pregnancy. The Cochrane Database of Systematic Reviews (1), CD005216.  
  
Wong, K. S., Ngai, C. S., Yeo, E. L., Tang, L. C., & Ho, P. C. (2000). A comparison of two regimens of intravaginal 
misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Human 
Reproduction, 15(3), 709-712.  
 
World Health Organization. (2012). Safe abortion: Technical and policy guidance for health systems (2nd ed.). 
Geneva: World Health Organization. 
 
  
Clinical Updates in Reproductive Health                        www.ipas.org/clinicalupdates 
 
                                                                          120 
 
Misoprostol for treatment of incomplete and missed 
abortion (postabortion care) for less than 13-week uterine 
size: Recommended regimen 
 
Recommendation: 
Incomplete abortion: Misoprostol 600mcg orally in a single dose or 400mcg sublingually in a 
single dose (WHO, 2012)  
 
Missed abortion: Misoprostol 800mcg vaginally in a single dose or 600mcg sublingually every 
three hours for a maximum of three doses (1,800mcg)  
  
Strength of recommendation: Strong 
  
Quality of evidence: Moderate 
  
Last reviewed:  October 31, 2015 
 
Definitions 
Incomplete abortion: An abortion—whether spontaneous or induced—in which some pregnancy tissue passes 
out of the uterus but some remains. 
  
Missed abortion: A kind of miscarriage; the pregnancy ends, but the tissue remains in the uterus. 
  
Incomplete abortion   
In a Cochrane review of 12 studies of 2,894 women presenting with incomplete abortion under 13 weeks, 
management with misoprostol showed a slightly lower incidence of completion compared to vacuum 
aspiration, but success rates were high for both methods (Neilson, Gyte, Hickey, Vazquez, & Dou, 2013). In the 
analysis, oral and sublingual misoprostol showed similar efficacy and side effect profiles. Lengthening the time 
to provider follow-up increases the success of misoprostol treatment.   
  
Missed abortion 
A single dose of misoprostol 800mcg vaginally results in successful uterine evacuation in more than 80% of 
women (Ngoc, Blum, Westheimer, Quan, & Winikoff, 2004). Some studies have used repeat doses of 
misoprostol 800mcg vaginally after 24 hours (Barcelo et al., 2012; Graziosi, Mol, Ankum, & Bruinse, 2004; 
Muffley, Stitely, & Gherman, 2002) or 72 hours (Gilles et al., 2004; Zhang et al., 2005) with a resulting increase 
in the complete abortion rates. However, it is unclear whether the increase in complete abortion is due to the 
additional prostaglandin dose or the increased time to evaluation.  
 
When women are managed expectantly after a single dose of misoprostol, their complete abortion rates 
increase over time (Ngoc et al., 2004). Misoprostol 600mcg sublingually repeated every three hours for a 
maximum of two more doses achieves similar success rates (Tang, Ong, Tse, Ng, Lee, & Ho, 2003; Tang et al., 
2006). A 2013 trial randomized 310 women, 91% of whom had early missed abortion, to receive either 400mcg 
or 800mcg of misoprostol vaginally as a single dose with a second dose 24 hours later if the products of 
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conception had not yet passed (Petersen et al., 2013). Both doses were equally effective in completing the 
abortion, although more women in the 400mcg group received a second dose of misoprostol. 
 
Young women 
This recommendation is the same for young women. In a secondary analysis of 485 misoprostol users (Creinin 
et al., 2006) nulliparity was associated with twice the likelihood of successful treatment with a single dose of 
800mcg vaginal misoprostol. 
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Misoprostol for treatment of incomplete and missed 
abortion (postabortion care) for more than 13-week uterine 
size (second trimester): Recommended regimen 
 
Recommendation: 
 Misoprostol in a dose of at least 200mcg vaginally, sublingually or buccally may be given every 
six hours. 
 Pretreatment with mifepristone 200mg orally 1-2 days before misoprostol may decrease the 
time from induction to expulsion. 
 The misoprostol-only or mifepristone-misoprostol regimen for induced abortion in the second 
trimester can be used. 
 Where skilled providers and supportive facilities exist, dilation and evacuation may be offered. 
 
Strength of recommendation: Strong 
  
Quality of evidence: Low 
  
Last reviewed:  October 31, 2015 
 
Background 
The majority of postabortion care research and programs focus on women in the first trimester with uterine 
size less than 13 weeks (Ipas, 2013). However, where unsafe abortion is prevalent, as many as 40% of women 
needing postabortion care present in the second trimester (Ministry of Health of Kenya, Ipas and Guttmacher 
Institute, 2013). Women may present with incomplete abortion, retained placenta, fetal demise or ruptured 
membranes, all of which require uterine evacuation. Currently, no widely recognized guidance exists regarding 
how to manage postabortion care at later gestations or larger uterine size (World Health Organization [WHO], 
2012).   
 
Medical regimens 
Evidence is limited to suggest the optimal medical regimen for second-trimester postabortion care, but a 
systematic review of the literature suggests that at least 200mcg vaginally, sublingually or buccally given every 
six hours is an effective regimen (Bracken, 2014; Mark, Borgatta, & Edelman, 2015). Pretreatment with 
mifepristone 1-2 days prior to misoprostol may reduce the time to expulsion (Stibbe, 2012). Expert opinion 
supports using regimens similar to second-trimester medical abortion until further evidence is generated 
(Mark, Borgatta, & Edelman, 2015).  
  
Dilatation and evacuation (D&E) 
No studies have compared medical management versus vacuum aspiration or D&E for postabortion care in the 
second trimester. However, D&E is recommended for induced abortions in the second trimester and can be 
offered to women for postabortion care where skilled providers and supportive facilities exist (WHO, 2012). 
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Young women 
This recommendation is the same for young women. 
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Vacuum aspiration for treatment of incomplete and missed 
abortion (postabortion care): Prophylactic antibiotics 
 
Recommendation:  
Routine prophylactic antibiotics are recommended for treatment of incomplete or missed abortion 
with vacuum aspiration (commonly referred to as postabortion care). Where antibiotics are 
unavailable, uterine aspiration may still be offered. Women with signs or symptoms of infection 
should be given therapeutic antibiotics. 
 
Strength of recommendation: Weak 
  
Quality of evidence: Very low 
  
Last reviewed: October 23, 2015 
 
Background 
Scant literature exists supporting routine antibiotics during vacuum aspiration for incomplete or missed 
abortion (commonly referred to as postabortion care) (May, Gülmezoglu, & Ba-Thike, 2007). However, routine 
prophylactic antibiotics are recommended before vacuum aspiration for induced abortion (World Health 
Organization [WHO], 2012), and therefore in the absence of evidence, it seems prudent to administer 
prophylactic antibiotics for vacuum aspiration when used for postabortion care, especially in areas where 
unsafe abortion is prevalent (Achilles & Reeves, 2011). The inability to provide antibiotics should not limit 
access to vacuum aspiration (WHO, 2012), as the overall risk of infection is low. 
 
Regimen 
Many antibiotic regimens for abortion prophylaxis have been studied, but the ideal antibiotic, dose and timing 
has not yet been established (Achilles & Reeves, 2011). Tetracyclines (doxycycline) and nitroimidazoles 
(metronidazole and tinidizole) are commonly used because of their clinical efficacy, oral availability, low cost 
and low risk of allergic reactions (Achilles & Reeves, 2011). A short pre-operative course of oral doxycycline or 
metronidazole may be used in clinical practice.     
 
Therapeutic antibiotics 
Women who present with signs and symptoms of infection should be treated with broad spectrum oral or 
intravenous antibiotics according to the severity of the infection. 
 
Quality of evidence 
A Cochrane review of antibiotics for incomplete abortion found only one randomized controlled trial from 
Zimbabwe with 140 women that showed no benefit from a course of oral tetracycline after uterine evacuation 
(May, Gülmezoglu, & Ba-Thike, 2007; Seeras, 1989). United States trials of prophylactic oral (Ramin et al., 1995) 
or intravenous (Prieto, Eriksen & Blanco, 1995) doxycycline and a Thai trial of intramuscular cefoxitin (Titipant & 
Cherdchoogieat, 2012) before evacuation for incomplete abortion have shown no reduction in postoperative 
infection with antibiotics.  
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Young women 
This recommendation is the same for young women. 
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Postabortion hemorrhage
Recommendation: 
When hemorrhage occurs, providers need to perform rapid diagnosis and management. Hemorrhage 
caused by atony may be treated with uterine massage, uterotonic medications, reaspiration, tamponade 
or surgery as a last resort. Women need close monitoring and treatment for shock. 
  
  
Strength of recommendation: Strong 
  
Quality of evidence: Low 
  
Last reviewed: October 28, 201 
 
Background 
Hemorrhage after abortion is rare, occurring in 0-3 per 1,000 cases following first-trimester vacuum aspiration, 
and 0.9-10 per 1,000 cases following second-trimester uterine evacuation (Kerns & Steinauer, 2013). Definitions 
of postabortion hemorrhage vary, making comparisons of incidence, risk factors and treatments across studies 
difficult. A definition proposed by the Society for Family Planning is excessive bleeding that requires a clinical 
response such as transfusion or hospital admission, and/or bleeding in excess of 500mL (Kerns & Steinauer, 2013). 
  
Diagnosis 
When postabortion hemorrhage is suspected, clinicians should take a rapid, systematic approach to assessing and 
treating women. Initial assessment includes an inspection of the cervix for laceration, a bimanual examination to 
assess for uterine atony, and ultrasound examination or repeat aspiration to evaluate for retained pregnancy-
related material or blood. 
  
Management 
Cervical lacerations may be treated with direct pressure with gauze or a sponge-holding forcep, application of 
topical clotting agents like Monsel’s solution and silver nitrate, or absorbable sutures. 
  
Uterine atony requires a rapid, sequential response starting with uterine massage, to uterotonics, reaspiration, 
uterine tamponade and finally to surgical measures. Providers should move quickly to the next step if bleeding is 
not controlled. When uterotonic medications are used, additional or repeat doses may be used if bleeding does 
not improve after the first dose.  
  
Uterotonic medications and dosages (Lichtenberg & Grimes, 2009) 
  
Medication Dosage 
Methylergonovine 0.2mg intramuscularly or intracervically; repeat after 15 minutes for a maximum 
of 5 doses. Avoid in women with hypertension 
Misoprostol 
 
200-800mcg orally, rectally or sublingually (World Health Organization, 2012) 
Oxytocin 20 units in 1L of intravenous fluid at a rate of 60 drops/minute; maximum of 3L of 
fluid 
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Intrauterine tamponade 
 
Sterile gauze, 30-75mL Foley catheter balloon or inflated condom placed in uterus. 
 
Reaspiration is appropriate if there is evidence of retained tissue or accumulation of blood in the uterus on 
ultrasound. 
  
If tamponade successfully stops the bleeding, the Foley balloon, gauze or inflated condom should be left in place 
for several hours while the patient is observed. If she remains stable after the balloon or gauze is removed, she 
may be discharged.   
  
Surgical measures like hysterectomy, uterine compression sutures, uterine artery ligation or uterine artery 
embolization can be performed for bleeding that cannot be controlled by other measures. Providers at health 
centers without available operating rooms or expertise should have clear protocols for resuscitation and transfer 
to a higher level of care.  
  
All women who experience postabortal bleeding should be managed appropriately for potential shock with IV line 
placement, supplemental oxygen, fluid resuscitation, and replacement of blood products as indicated. 
  
Young women 
This recommendation is the same for young women. 
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Pain medication table 
Though the medications shown below are commonly used for pain management during vacuum aspiration and dilatation and evacuation, many other 
options exist. This table does not cover general anesthetic agents.  
Both anxiolytics and narcotics may cause respiratory depression, especially when they are used together. Accordingly, lower doses should be used when 
they are together than when they are separate. When medications are given intravenously immediately before a procedure they should be given slowly 
and intermittently by a specially trained provider. Problematic side effects can be avoided by repeated small intravenous doses that are titrated to a 
woman’s level of pain and sedation. The peak analgesic effect should occur during the procedure to avoid excessive postprocedure sedation.  
Even clinicians using lighter sedation analgesia must be able to manage respiratory arrest, in the unlikely event that an unintentional overdose should 
occur. Providers should be trained in airway management and cardiopulmonary resuscitation, and resuscitative equipment and appropriate antagonist 
drugs (naloxone and flumazenil) should be available. 
Disclaimer: This resource is designed to be a supplemental resource for clinicians and is NOT intended to serve as a replacement for drug label information 
or clinical judgment that accounts for patients' and facilities' unique circumstances. 
Last reviewed: November 4, 2015 
Drug type Generic drug 
name 
Dose and timing Half-life Side effects Comments 
Local anesthetic Xylocaine 15-20ml of 0.5-1% solution in a 
paracervical block not to exceed 
4.5mg/kg 
60-90 minutes Buzzing in ears; 
dizziness; numbness in 
lips, mouth and tongue; 
metallic taste; seizures 
(rare) 
 Pull back plunger before injecting to avoid 
intravascular injection. Wait 3 minutes for 
medication to take effect  
 Mild reaction (itching, rash, and hives) can be 
treated with 25-50mg diphenhydramine IM or IV 
 For intense reaction or respiratory distress, obtain 
IV access immediately. Give epinephrine 0.4mg 
subcutaneously and diazepam 5mg slow IV push  
 Support respiration. If wheezing is present, inhaler 
may be helpful 
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 Allergic reaction is very rare. Reactions that do 
occur may be due to preservatives in multi-dose 
vials. Preservative-free lidocaine allergy is 
extremely rare  
Nonsteroidal anti-
inflammatory drug 
(NSAID)   
Ibuprofen Oral: 400-800mg 1 hour before the 
procedure 
4-6 hours Possible gastrointestinal 
upset 
Do not use in women with active peptic ulcer disease 
or renal failure 
Naproxen Oral: 550mg 1 hour before the 
procedure 
4-6 hours Possible gastrointestinal 
upset 
Do not use in women with active peptic ulcer disease 
or renal failure 
Ketorolac Oral: 20mg 1 hour before procedure  
IV: 30mg over at least 15 seconds 30-
60 minutes before procedure 
IM: 60mg 30-60 minutes before 
procedure 
For women less than 50kg, all doses 
should be halved 
4-6 hours   Single dose IM ketorolac prior to surgery may 
reduce opioid use and postoperative pain (de 
Oliveira, 2012; Roche, 2011) 
 Do not use in women with active peptic ulcer 
disease, renal failure, breastfeeding or sensitivity 
to other NSAIDs 
 Breakthrough pain should be managed with 
narcotics rather than increasing ketorolac beyond 
the recommended doses  
Analgesic Acetaminophen Oral: 500-1,000mg 30-60 minutes 
before procedure 
3-6 hours   Not a first-line pain medication for vacuum 
aspiration or medical abortion. May be used as an 
antipyretic  
 Liver toxicity from overdose (maximum dose = 
4,000mg/day) is a risk 
Narcotic/analgesic 
combination  
Acetaminophen 
300mg + codeine 
30mg 
Oral: 1-2 tablets 1 hour before 
procedure 
3-6 hours Drowsiness, light-
headedness, nausea 
and vomiting,  
decreased breathing 
 If respiration is compromised, assist with 
breathing (airway management, oxygen and ambu 
bag) and reverse with naloxone (see end of chart)  
 Be aware of combining with other acetaminophen 
containing products. Liver toxicity from overdose 
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rate, loss of 
consciousness 
of acetaminophen (maximum dose = 4,000 
mg/day) is a risk. 
Acetaminophen 
500mg + 
hydrocodone 5mg 
Oral: 1-2 tablets 1 hour before 
procedure 
4-6 hours Drowsiness, light-
headedness, nausea 
and vomiting,  
decreased breathing 
rate, loss of 
consciousness 
 If respiration is compromised, assist with 
breathing (airway management, oxygen and ambu 
bag) and reverse with naloxone (see end of chart)  
 Be aware of combining with other 
acetaminophen-containing products. Liver toxicity 
from overdose of acetaminophen (maximum dose 
= 4,000 mg/day) is a risk 
Narcotic   Meperidine Oral: 100-150mg 30-60 minutes 
before procedure 
IV: 25-50mg 5-15 minutes prior to 
procedure 
IM/SC: 50-100mg 30-90 minutes 
prior to procedure 
4-6 hours Drowsiness, light-
headedness, nausea 
and vomiting,  
decreased breathing 
rate, loss of 
consciousness,, 
hypotension, seizures 
 If respiration is compromised, assist with 
breathing (airway management, oxygen and ambu 
bag) and reverse with naloxone (see end of chart)  
 More rapid onset and shorter duration of action 
than morphine  
 Meperidine 60-80mg = morphine 10mg 
Fentanyl IV: 50-100mcg immediately before 
procedure (may repeat every 10-15 
minutes, not to exceed 250mcg) 
IM: 50-100mcg 30-60 minutes before 
procedure 
30-60 minutes Drowsiness, light-
headedness, weakness, 
bradycardia, decreased 
breathing rate, loss of 
consciousness,, 
hypotension, seizures 
 If respiration is compromised, assist with 
breathing (airway management, oxygen and ambu 
bag) and reverse with naloxone (see end of chart)  
 More rapid onset and shorter duration of action 
than meperidine 
 Fentanyl 100mcg = meperidine 75mg = morphine 
10mg 
 Onset of action is 2-7 minutes when given IV 
 
Tramadol IV/IM: 50-100mg 15-30 minutes 
before the procedure 
4-6 hours Drowsiness, light-
headedness, sweating, 
weakness, fatigue, 
seizures 
 If respiration is compromised, assist with 
breathing (airway management, oxygen and ambu 
bag) and reverse with diazepam  
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Oral/suppository: 50-100mg 60-90 
minutes prior to the procedure 
 
 Less respiratory depression than morphine or 
meperidine 
 Tramadol 100mcg = morphine 10mg 
Anxiolytic 
(Benzodiazepine)   
Diazepam Oral: 10mg 1 hour before procedure 
IV: 2-5mg IV 20 minutes before 
procedure 
21-37 hours Blurred vision, dizziness, 
disorientation, pain and 
redness on injection, 
decreased breathing 
rate, loss of 
consciousness 
 If respiration is compromised, assist with 
breathing (airway management, oxygen and ambu 
bag) and reverse with flumazenil (see end of 
chart) 
 Has a mild amnestic effect 
 Onset of action is 2-10 minutes when given IV 
Midazolam IV: 1-2mg immediately before the 
procedure, then 0.5-1mg IV every 5 
minutes as needed, not to exceed 
5mg 
IM: 0.07-0.08mg/kg or about 5mg up 
to 1 hour before procedure 
1-4 hours Blurred vision, dizziness, 
disorientation, CNS and 
respiratory depression 
 If respiration is compromised, assist with 
breathing (airway management, oxygen and ambu 
bag) and reverse with flumazenil (see end of 
chart)  
 Midazolam 2.5mg = diazepam 10mg 
 Stronger amnestic effect than diazepam 
 Onset of action is 1-5 minutes when given IV and 
15-30 minutes when given IM  
Lorazepam Oral: 1-2mg 30-60 minutes before 
procedure 
IV: 2mg given over 1 minute 
immediately before the procedure 
IM: 0.05mg/kg up to a maximum of 
4mg within 2 hours before the 
procedure 
14 hours Blurred vision, dizziness, 
disorientation, 
decreased breathing 
rate, loss of 
consciousness 
 If respiration is compromised, assist with 
breathing (airway management, oxygen and ambu 
bag) and reverse with flumazenil (see end of 
chart) 
 Amnestic effect  
 Occasionally may increase patient anxiety 
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Reversal agent for 
narcotic 
Naloxone IV: 0.4mg vial mixed in 10mL saline. 
Give 1mL (40mcg/mL) every 2 
minutes until reversal is seen 
   Naloxone's duration of action is 1 hour and may wear 
off before the narcotic. Therefore, patients treated 
with naloxone must be monitored closely for several 
hours 
 Maintain airway and respirations while giving 
naloxone 
Reversal agent for 
benzodiazepine 
Flumazenil IV: 0.2mg every minute until 
respirations return. Do not exceed 
1mg  
    Flumazenil's duration of action is 1 hour and may 
wear off before the benzodiazepine. Therefore, 
patients treated with flumazenil must be 
monitored closely for several hours. In the event 
of overdose with narcotic and benzodiazepine, 
reverse the narcotic first with naloxone and use 
flumazenil subsequently if needed  
 Maintain airway and respirations while giving 
flumazenil 
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Making Ipas clinical recommendations 
 
When a specific clinical recommendation is made within Ipas’s Clinical Updates in Reproductive 
Health, there are two elements included to help put the clinical information in perspective: 
     1. Quality of evidence 
     2. Strength of the recommendation 
 
Quality of evidence reflects the extent to which we can be confident that an estimate of the effect of 
an intervention is adequate to support recommendations (Guyatt et al., 2008). 
  
Strength of a recommendation reflects the extent to which we can be confident that the desirable 
effects of an intervention outweigh the undesirable effects (Guyatt, Oxman, Kunz, Falck-Ytter et al., 
2008). In other words, adherence to the recommendation will do more good than harm.   
  
Last reviewed: November 4, 2015 
 
Quality of evidence 
Clinical evidence, and the recommendations based on the evidence, can be of varying quality. Sources of 
evidence range from small studies or case reports to well-designed large clinical studies that have minimized 
bias. The quality of evidence is defined as the "extent to which one can be confident that an estimate of effect 
or association is correct."  
  
When assessing the quality of evidence, the following criteria are considered (Oxman & Group, 2004):  
1. the study design 
2. the consistency of the results across available studies 
3. precision of the results (wide or narrow confidence intervals) 
4. the applicability with respect to populations, interventions and settings where the proposed 
intervention may be used 
5. the likelihood of publication bias  
  
Ipas uses the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
system, a four-level system of grading quality of evidence that works as follows:  
  
 A high grade is assigned when further research is very unlikely to change our confidence in the estimate 
of effect.   
 A moderate grade indicates that further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate.   
 A low grade indicates that further research is very likely to have an important impact on our confidence 
in the estimate of effect and is likely to change the estimate.   
 A very low grade is reserved for when any estimate of effect is very uncertain. 
   
Based on these grading criteria, randomized trials are initially given a high grade, observational studies are 
initially labeled as having a low quality of evidence, and any other evidence is very low. However, the grade 
could decrease if the evidence is based on poor study quality, inconsistent results, indirect evidence, imprecise 
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or sparse data, or a high probability of reporting bias. The grade could increase if there is a strong association 
between the intervention and the outcome. 
 
Strength of a recommendation 
Strength of recommendation is determined by the balance between desirable and undesirable consequences of 
alternative management strategies (for example, manual vacuum aspiration versus dilatation and curettage), 
quality of evidence, variability in clients’ values and preferences, and resource availability and use (Guyatt, 
Oxman, Kunz, Falck-Ytter et al., 2008). Desirable effects can include improved health outcomes, less burden for 
providers and health systems, and greater savings. Undesirable effects can include harm to patients, greater 
burden (for example, the demands of adhering to an onerous recommendation) and increased costs. 
  
Strong recommendations are granted when the desirable effects of an intervention or adherence with a 
recommendation clearly outweigh the undesirable effects (Guyatt, Oxman, Vist et al., 2008).   
  
Weak recommendations are made when evidence suggests that desirable effects of an intervention and 
recommendation probably outweigh the undesirable effects but there are small benefits or benefits that may 
not be worth the costs, and there is an absence of high-quality evidence (Guyatt, Oxman, Vist et al., 2008). 
  
The difficulty in developing guidelines based on quality of evidence is that the studies evaluated may not have 
comparable patient populations, health-care settings or resources as those contexts to which the 
recommendations are targeted. Those developing guidelines should take into account the patient population, 
nature of the intervention, cost-effectiveness and opportunity cost of an alternate intervention, feasibility of 
intervention in the specified health-care setting, and societal cost (Guyatt, Oxman, Vist et al., 2008; Guyatt, 
Oxman, Kunz, Jaeschke et al., 2008; World Health Organization [WHO], 2012). Similar to the WHO's approach, 
Ipas should help countries “localize” recommendations by providing technical assistance when necessary.   
  
Can you have a strong recommendation based on low-quality evidence? 
 
Yes. There are many factors that influence the strength of a recommendation.  
  
For example, although there is limited evidence about the safety and efficacy of providing hormonal 
contraception during medical abortion, several factors increase the strength of the recommendation that 
women can be offered hormonal contraception at the time of the first pill of a medical abortion regimen: 1) the 
value of integrating contraception into abortion care to prevent unintended pregnancy, 2) the low theoretical 
risk that it interferes with the mechanism of action of mifepristone or misoprostol, and 3) the risk that women 
who do not get a contraceptive method at the time of abortion will not return for it later. 
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